MXPA99010045A - Procedure for the purification of recombinant human erythropoyetine from recombinant cell culture supplementers and human erythropoyetin obtained with such procedime - Google Patents
Procedure for the purification of recombinant human erythropoyetine from recombinant cell culture supplementers and human erythropoyetin obtained with such procedimeInfo
- Publication number
- MXPA99010045A MXPA99010045A MXPA/A/1999/010045A MX9910045A MXPA99010045A MX PA99010045 A MXPA99010045 A MX PA99010045A MX 9910045 A MX9910045 A MX 9910045A MX PA99010045 A MXPA99010045 A MX PA99010045A
- Authority
- MX
- Mexico
- Prior art keywords
- erythropoietin
- human
- cells
- epo
- recombinant
- Prior art date
Links
- 241000282414 Homo sapiens Species 0.000 title claims abstract description 145
- 238000000034 method Methods 0.000 title claims abstract description 42
- 238000000746 purification Methods 0.000 title claims description 27
- 238000004113 cell culture Methods 0.000 title claims description 5
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 11
- 238000011026 diafiltration Methods 0.000 claims abstract description 9
- 238000004191 hydrophobic interaction chromatography Methods 0.000 claims abstract description 4
- 238000001556 precipitation Methods 0.000 claims abstract description 4
- 238000005227 gel permeation chromatography Methods 0.000 claims abstract 2
- 108090000394 Erythropoietin Proteins 0.000 claims description 260
- 102000003951 Erythropoietin Human genes 0.000 claims description 260
- 229940105423 erythropoietin Drugs 0.000 claims description 260
- 239000011159 matrix material Substances 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 13
- 230000002209 hydrophobic Effects 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 229920002684 Sepharose Polymers 0.000 claims description 6
- 102000001708 Protein Isoforms Human genes 0.000 claims description 4
- 108010029485 Protein Isoforms Proteins 0.000 claims description 4
- 238000005349 anion exchange Methods 0.000 claims description 4
- 238000005571 anion exchange chromatography Methods 0.000 claims description 4
- 238000005341 cation exchange Methods 0.000 claims description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 claims description 3
- 235000011130 ammonium sulphate Nutrition 0.000 claims description 3
- 238000005277 cation exchange chromatography Methods 0.000 claims description 3
- 239000012228 culture supernatant Substances 0.000 claims description 3
- 238000001502 gel electrophoresis Methods 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- BFNBIHQBYMNNAN-UHFFFAOYSA-N Ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 claims description 2
- 239000012506 Sephacryl® Substances 0.000 claims description 2
- 238000002270 exclusion chromatography Methods 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000005119 centrifugation Methods 0.000 claims 1
- 230000002441 reversible Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 abstract description 46
- 108090000623 proteins and genes Proteins 0.000 abstract description 46
- 230000000694 effects Effects 0.000 abstract description 25
- 238000011084 recovery Methods 0.000 abstract description 10
- 241000282412 Homo Species 0.000 abstract description 9
- 238000004587 chromatography analysis Methods 0.000 abstract description 5
- 239000003960 organic solvent Substances 0.000 abstract description 4
- 230000002588 toxic Effects 0.000 abstract description 4
- 231100000331 toxic Toxicity 0.000 abstract description 4
- 125000002091 cationic group Chemical group 0.000 abstract description 2
- 125000000129 anionic group Chemical group 0.000 abstract 1
- 210000004027 cells Anatomy 0.000 description 133
- 230000014509 gene expression Effects 0.000 description 70
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 65
- 235000018102 proteins Nutrition 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 210000004369 Blood Anatomy 0.000 description 38
- 241000699666 Mus <mouse, genus> Species 0.000 description 38
- 239000008280 blood Substances 0.000 description 38
- 229920002676 Complementary DNA Polymers 0.000 description 33
- 239000002299 complementary DNA Substances 0.000 description 33
- 238000004519 manufacturing process Methods 0.000 description 30
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 27
- 238000000926 separation method Methods 0.000 description 26
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 25
- 239000000243 solution Substances 0.000 description 22
- 208000007502 Anemia Diseases 0.000 description 20
- 238000010367 cloning Methods 0.000 description 20
- 102000004419 dihydrofolate reductase family Human genes 0.000 description 20
- 108020001096 dihydrofolate reductase family Proteins 0.000 description 20
- 238000002955 isolation Methods 0.000 description 19
- 239000000463 material Substances 0.000 description 18
- 239000000523 sample Substances 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 241000699802 Cricetulus griseus Species 0.000 description 16
- 102000003886 Glycoproteins Human genes 0.000 description 16
- 108090000288 Glycoproteins Proteins 0.000 description 16
- 210000003734 Kidney Anatomy 0.000 description 16
- 238000010192 crystallographic characterization Methods 0.000 description 16
- 210000001672 Ovary Anatomy 0.000 description 15
- 239000000427 antigen Substances 0.000 description 15
- 102000038129 antigens Human genes 0.000 description 15
- 108091007172 antigens Proteins 0.000 description 15
- 210000004962 mammalian cells Anatomy 0.000 description 15
- 230000002485 urinary Effects 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 14
- 210000002381 Plasma Anatomy 0.000 description 13
- 238000000338 in vitro Methods 0.000 description 12
- 241000282693 Cercopithecidae Species 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 230000003321 amplification Effects 0.000 description 11
- 238000004166 bioassay Methods 0.000 description 11
- 238000003199 nucleic acid amplification method Methods 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 208000009863 Chronic Kidney Failure Diseases 0.000 description 10
- 241000699800 Cricetinae Species 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 10
- 229920000272 Oligonucleotide Polymers 0.000 description 10
- 230000033228 biological regulation Effects 0.000 description 10
- 150000001720 carbohydrates Chemical class 0.000 description 10
- 238000009396 hybridization Methods 0.000 description 10
- 230000002194 synthesizing Effects 0.000 description 10
- 229920001850 Nucleic acid sequence Polymers 0.000 description 9
- 108020004511 Recombinant DNA Proteins 0.000 description 9
- 241000283898 Ovis Species 0.000 description 8
- 210000002966 Serum Anatomy 0.000 description 8
- 230000000913 erythropoietic Effects 0.000 description 8
- 150000002482 oligosaccharides Polymers 0.000 description 8
- 239000012071 phase Substances 0.000 description 8
- 230000001105 regulatory Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 229910000162 sodium phosphate Inorganic materials 0.000 description 8
- 241000701822 Bovine papillomavirus Species 0.000 description 7
- 230000004544 DNA amplification Effects 0.000 description 7
- 208000002672 Hepatitis B Diseases 0.000 description 7
- 102000014150 Interferons Human genes 0.000 description 7
- 108010050904 Interferons Proteins 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 230000001580 bacterial Effects 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 229920002106 messenger RNA Polymers 0.000 description 7
- 108010045030 monoclonal antibodies Proteins 0.000 description 7
- 102000005614 monoclonal antibodies Human genes 0.000 description 7
- 235000019799 monosodium phosphate Nutrition 0.000 description 7
- 238000011012 sanitization Methods 0.000 description 7
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 7
- 241000712461 unidentified influenza virus Species 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- 108020004999 Messenger RNA Proteins 0.000 description 6
- 101710043164 Segment-4 Proteins 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 6
- 101700038759 VP1 Proteins 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 108090001123 antibodies Proteins 0.000 description 6
- 102000004965 antibodies Human genes 0.000 description 6
- 235000014633 carbohydrates Nutrition 0.000 description 6
- 230000002759 chromosomal Effects 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 230000002068 genetic Effects 0.000 description 6
- 101700005460 hemA Proteins 0.000 description 6
- 239000000185 hemagglutinin Substances 0.000 description 6
- 230000001146 hypoxic Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000001131 transforming Effects 0.000 description 6
- 210000003743 Erythrocytes Anatomy 0.000 description 5
- 208000006572 Human Influenza Diseases 0.000 description 5
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 5
- 210000004185 Liver Anatomy 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 206010038444 Renal failure chronic Diseases 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 230000004069 differentiation Effects 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 230000000925 erythroid Effects 0.000 description 5
- 230000001939 inductive effect Effects 0.000 description 5
- 229960000485 methotrexate Drugs 0.000 description 5
- 229920001542 oligosaccharide Polymers 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000003127 radioimmunoassay Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000035897 transcription Effects 0.000 description 5
- 210000000349 Chromosomes Anatomy 0.000 description 4
- 229940088597 Hormone Drugs 0.000 description 4
- 206010022000 Influenza Diseases 0.000 description 4
- 102000003996 Interferon beta Human genes 0.000 description 4
- 108090000467 Interferon beta Proteins 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 4
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 4
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 210000004102 animal cell Anatomy 0.000 description 4
- 201000000522 chronic kidney disease Diseases 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 230000001605 fetal Effects 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000001965 increased Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 210000000287 oocyte Anatomy 0.000 description 4
- 230000000268 renotropic Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 229960005486 vaccines Drugs 0.000 description 4
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 210000003013 Erythroid Precursor Cells Anatomy 0.000 description 3
- 206010015281 Erythroleukaemia Diseases 0.000 description 3
- 102100006624 F9 Human genes 0.000 description 3
- 108010076282 Factor IX Proteins 0.000 description 3
- 241000700721 Hepatitis B virus Species 0.000 description 3
- 229940092253 Ovalbumin Drugs 0.000 description 3
- 108010058846 Ovalbumin Proteins 0.000 description 3
- 108091005771 Peptidases Proteins 0.000 description 3
- HKOOXMFOFWEVGF-UHFFFAOYSA-N Phenylhydrazine Chemical compound NNC1=CC=CC=C1 HKOOXMFOFWEVGF-UHFFFAOYSA-N 0.000 description 3
- 208000008601 Polycythemia Diseases 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 206010038389 Renal cancer Diseases 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 241000269368 Xenopus laevis Species 0.000 description 3
- 230000000603 anti-haemophilic Effects 0.000 description 3
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 3
- 108091006028 chimera Proteins 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 108010038292 erythrotropin Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229960004222 factor IX Drugs 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000003899 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 230000011132 hemopoiesis Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 230000004807 localization Effects 0.000 description 3
- 229960000060 monoclonal antibodies Drugs 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229940067157 phenylhydrazine Drugs 0.000 description 3
- 230000000581 polycythemic Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 201000010174 renal carcinoma Diseases 0.000 description 3
- 230000003362 replicative Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000001225 therapeutic Effects 0.000 description 3
- 108010061238 threonyl-glycine Proteins 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N 2-((2,6-Dichlorophenyl)imino)imidazolidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- TUTIHHSZKFBMHM-UHFFFAOYSA-N 4-amino-5-[(3-amino-1-carboxy-3-oxopropyl)amino]-5-oxopentanoic acid Chemical compound OC(=O)CCC(N)C(=O)NC(CC(N)=O)C(O)=O TUTIHHSZKFBMHM-UHFFFAOYSA-N 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 229920001405 Coding region Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 108010074604 Epoetin Alfa Proteins 0.000 description 2
- 229960003388 Epoetin alfa Drugs 0.000 description 2
- 210000003754 Fetus Anatomy 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 229940065521 Glucocorticoid inhalants for obstructive airway disease Drugs 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 241000701109 Human adenovirus 2 Species 0.000 description 2
- 108090000745 Immune Sera Proteins 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N Indometacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 208000001083 Kidney Disease Diseases 0.000 description 2
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 2
- NFNVDJGXRFEYTK-YUMQZZPRSA-N Leu-Glu Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O NFNVDJGXRFEYTK-YUMQZZPRSA-N 0.000 description 2
- 208000009503 Leukemia, Erythroblastic, Acute Diseases 0.000 description 2
- 210000004072 Lung Anatomy 0.000 description 2
- ATIPDCIQTUXABX-UWVGGRQHSA-N Lys-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCCN ATIPDCIQTUXABX-UWVGGRQHSA-N 0.000 description 2
- 230000036740 Metabolism Effects 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 230000004988 N-glycosylation Effects 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010058116 Nephrogenic anaemia Diseases 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241001504519 Papio ursinus Species 0.000 description 2
- 102000035443 Peptidases Human genes 0.000 description 2
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 2
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 210000003324 RBC Anatomy 0.000 description 2
- 241000711798 Rabies lyssavirus Species 0.000 description 2
- 210000000952 Spleen Anatomy 0.000 description 2
- 229940037128 Systemic Glucocorticoids Drugs 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 241000700618 Vaccinia virus Species 0.000 description 2
- WITCOKQIPFWQQD-FSPLSTOPSA-N Val-Asn Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O WITCOKQIPFWQQD-FSPLSTOPSA-N 0.000 description 2
- 241000269961 Xiphiidae Species 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 238000005377 adsorption chromatography Methods 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229960000074 biopharmaceuticals Drugs 0.000 description 2
- 230000037348 biosynthesis Effects 0.000 description 2
- 239000000356 contaminant Substances 0.000 description 2
- 230000000875 corresponding Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 201000009910 diseases by infectious agent Diseases 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005755 formation reaction Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 108010026195 glycanase Proteins 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000003394 haemopoietic Effects 0.000 description 2
- 230000002440 hepatic Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved Effects 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000035786 metabolism Effects 0.000 description 2
- 238000000520 microinjection Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 239000002751 oligonucleotide probe Substances 0.000 description 2
- 210000000056 organs Anatomy 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 230000002572 peristaltic Effects 0.000 description 2
- 230000036231 pharmacokinetics Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108010066381 preproinsulin Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002829 reduced Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229960000187 tissue plasminogen activator Drugs 0.000 description 2
- 210000001519 tissues Anatomy 0.000 description 2
- 238000010361 transduction Methods 0.000 description 2
- 230000026683 transduction Effects 0.000 description 2
- 230000003612 virological Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- ZZKNRXZVGOYGJT-VKHMYHEASA-N (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid Chemical compound OC(=O)C[C@@H](C(O)=O)NC(=O)CP(O)(O)=O ZZKNRXZVGOYGJT-VKHMYHEASA-N 0.000 description 1
- RXGLHDWAZQECBI-SRVKXCTJSA-N (2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxypropanoic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O RXGLHDWAZQECBI-SRVKXCTJSA-N 0.000 description 1
- LZDNBBYBDGBADK-KBPBESRZSA-N (2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 LZDNBBYBDGBADK-KBPBESRZSA-N 0.000 description 1
- OZRNSSUDZOLUSN-LBPRGKRZSA-M (4S)-4-[[4-[(2-amino-4-oxo-7,8-dihydro-1H-pteridin-6-yl)methylamino]benzoyl]amino]-5-hydroxy-5-oxopentanoate Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-M 0.000 description 1
- XUUXCWCKKCZEAW-YFKPBYRVSA-N 2-[[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetic acid Chemical compound OC(=O)CNC(=O)[C@@H](N)CCCN=C(N)N XUUXCWCKKCZEAW-YFKPBYRVSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-Phosphoglyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- 229940030486 ANDROGENS Drugs 0.000 description 1
- 101000447387 APOA1 Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002068 Anaemia neonatal Diseases 0.000 description 1
- JQFZHHSQMKZLRU-IUCAKERBSA-N Arg-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N JQFZHHSQMKZLRU-IUCAKERBSA-N 0.000 description 1
- IJYZHIOOBGIINM-WDSKDSINSA-N Arg-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCN=C(N)N IJYZHIOOBGIINM-WDSKDSINSA-N 0.000 description 1
- XTWSWDJMIKUJDQ-RYUDHWBXSA-N Arg-Tyr Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XTWSWDJMIKUJDQ-RYUDHWBXSA-N 0.000 description 1
- XNSKSTRGQIPTSE-UHFFFAOYSA-N Arginyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CCCNC(N)=N XNSKSTRGQIPTSE-UHFFFAOYSA-N 0.000 description 1
- OAMLVOVXNKILLQ-BQBZGAKWSA-N Asp-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC(O)=O OAMLVOVXNKILLQ-BQBZGAKWSA-N 0.000 description 1
- DWBZEJHQQIURML-IMJSIDKUSA-N Asp-Ser Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CO)C(O)=O DWBZEJHQQIURML-IMJSIDKUSA-N 0.000 description 1
- 229960001230 Asparagine Drugs 0.000 description 1
- OMSMPWHEGLNQOD-UHFFFAOYSA-N Asparaginyl-Phenylalanine Chemical compound NC(=O)CC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 OMSMPWHEGLNQOD-UHFFFAOYSA-N 0.000 description 1
- NTQDELBZOMWXRS-UHFFFAOYSA-N Aspartyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC(O)=O NTQDELBZOMWXRS-UHFFFAOYSA-N 0.000 description 1
- 241000713836 Avian myelocytomatosis virus Species 0.000 description 1
- 206010003885 Azotaemia Diseases 0.000 description 1
- 210000002960 BFU-E Anatomy 0.000 description 1
- 210000000601 Blood Cells Anatomy 0.000 description 1
- 230000037227 Blood Loss Effects 0.000 description 1
- 102100006400 CSF2 Human genes 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 210000000170 Cell Membrane Anatomy 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- YXQDRIRSAHTJKM-IMJSIDKUSA-N Cys-Ser Chemical compound SC[C@H](N)C(=O)N[C@@H](CO)C(O)=O YXQDRIRSAHTJKM-IMJSIDKUSA-N 0.000 description 1
- RGTVXXNMOGHRAY-UHFFFAOYSA-N Cysteinyl-Arginine Chemical compound SCC(N)C(=O)NC(C(O)=O)CCCNC(N)=N RGTVXXNMOGHRAY-UHFFFAOYSA-N 0.000 description 1
- 108009000097 DNA Replication Proteins 0.000 description 1
- 230000026774 DNA mediated transformation Effects 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 241000388186 Deltapapillomavirus 4 Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 235000004418 Durio kutejensis Nutrition 0.000 description 1
- 108010027570 EC 2.4.2.22 Proteins 0.000 description 1
- 108010091358 EC 2.4.2.8 Proteins 0.000 description 1
- 102000018251 EC 2.4.2.8 Human genes 0.000 description 1
- 102100016635 EPOR Human genes 0.000 description 1
- 102000033147 ERVK-25 Human genes 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 210000004494 Erythroblasts Anatomy 0.000 description 1
- 210000003617 Erythrocyte Membrane Anatomy 0.000 description 1
- 108010075944 Erythropoietin Receptors Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 230000036826 Excretion Effects 0.000 description 1
- 101000401077 F8 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000287227 Fringillidae Species 0.000 description 1
- 102100008842 GH1 Human genes 0.000 description 1
- 101700047294 GPT2 Proteins 0.000 description 1
- 102000016876 Galactokinase Human genes 0.000 description 1
- 108091000074 Galactokinase Proteins 0.000 description 1
- LOJYQMFIIJVETK-WDSKDSINSA-N Gln-Gln Chemical compound NC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(O)=O LOJYQMFIIJVETK-WDSKDSINSA-N 0.000 description 1
- JEFZIKRIDLHOIF-BYPYZUCNSA-N Gln-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)NCC(O)=O JEFZIKRIDLHOIF-BYPYZUCNSA-N 0.000 description 1
- JZDHUJAFXGNDSB-WHFBIAKZSA-N Glu-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O JZDHUJAFXGNDSB-WHFBIAKZSA-N 0.000 description 1
- YBTCBQBIJKGSJP-BQBZGAKWSA-N Glu-Pro Chemical compound OC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O YBTCBQBIJKGSJP-BQBZGAKWSA-N 0.000 description 1
- CLSDNFWKGFJIBZ-UHFFFAOYSA-N Glutaminyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CCC(N)=O CLSDNFWKGFJIBZ-UHFFFAOYSA-N 0.000 description 1
- MFBYPDKTAJXHNI-VKHMYHEASA-N Gly-Cys Chemical compound [NH3+]CC(=O)N[C@@H](CS)C([O-])=O MFBYPDKTAJXHNI-VKHMYHEASA-N 0.000 description 1
- PNMUAGGSDZXTHX-BYPYZUCNSA-N Gly-Gln Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(N)=O PNMUAGGSDZXTHX-BYPYZUCNSA-N 0.000 description 1
- IEFJWDNGDZAYNZ-BYPYZUCNSA-N Gly-Glu Chemical compound NCC(=O)N[C@H](C(O)=O)CCC(O)=O IEFJWDNGDZAYNZ-BYPYZUCNSA-N 0.000 description 1
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000006390 HLA-B Antigens Human genes 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 102000008015 Hemeproteins Human genes 0.000 description 1
- 108010089792 Hemeproteins Proteins 0.000 description 1
- 206010067388 Hepatic angiosarcoma Diseases 0.000 description 1
- 206010073071 Hepatocellular carcinoma Diseases 0.000 description 1
- 241001622557 Hesperia Species 0.000 description 1
- 241000598171 Human adenovirus sp. Species 0.000 description 1
- 210000004408 Hybridomas Anatomy 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 229960000905 Indomethacin Drugs 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004218 Insulin-like growth factor I Human genes 0.000 description 1
- 108090000723 Insulin-like growth factor I Proteins 0.000 description 1
- 229940047124 Interferons Drugs 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 229940076264 Interleukin-3 Drugs 0.000 description 1
- 210000000936 Intestines Anatomy 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- SENJXOPIZNYLHU-IUCAKERBSA-N Leu-Arg Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N SENJXOPIZNYLHU-IUCAKERBSA-N 0.000 description 1
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 1
- LESXFEZIFXFIQR-LURJTMIESA-N Leu-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(O)=O LESXFEZIFXFIQR-LURJTMIESA-N 0.000 description 1
- LRKCBIUDWAXNEG-CSMHCCOUSA-N Leu-Thr Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRKCBIUDWAXNEG-CSMHCCOUSA-N 0.000 description 1
- JYOAXOMPIXKMKK-UHFFFAOYSA-N Leucyl-Glutamine Chemical compound CC(C)CC(N)C(=O)NC(C(O)=O)CCC(N)=O JYOAXOMPIXKMKK-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- UGTZHPSKYRIGRJ-YUMQZZPRSA-N Lys-Glu Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UGTZHPSKYRIGRJ-YUMQZZPRSA-N 0.000 description 1
- 235000005058 Madhuca longifolia Nutrition 0.000 description 1
- 240000004212 Madhuca longifolia Species 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- ADHNYKZHPOEULM-BQBZGAKWSA-N Met-Glu Chemical compound CSCC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O ADHNYKZHPOEULM-BQBZGAKWSA-N 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 108010066427 N-valyltryptophan Proteins 0.000 description 1
- 210000000885 Nephrons Anatomy 0.000 description 1
- 206010029151 Nephropathy Diseases 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 210000004940 Nucleus Anatomy 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000003154 Papilloma Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- OZILORBBPKKGRI-RYUDHWBXSA-N Phe-Arg Chemical compound NC(N)=NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=CC=C1 OZILORBBPKKGRI-RYUDHWBXSA-N 0.000 description 1
- FSXRLASFHBWESK-HOTGVXAUSA-N Phe-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 FSXRLASFHBWESK-HOTGVXAUSA-N 0.000 description 1
- 102000030951 Phosphotransferases Human genes 0.000 description 1
- 108091000081 Phosphotransferases Proteins 0.000 description 1
- 241001272996 Polyphylla fullo Species 0.000 description 1
- 206010036181 Porphyria Diseases 0.000 description 1
- 241000097929 Porphyria Species 0.000 description 1
- HMNSRTLZAJHSIK-YUMQZZPRSA-N Pro-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1 HMNSRTLZAJHSIK-YUMQZZPRSA-N 0.000 description 1
- UEKYKRQIAQHOOZ-KBPBESRZSA-N Pro-Trp Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)[O-])C(=O)[C@@H]1CCC[NH2+]1 UEKYKRQIAQHOOZ-KBPBESRZSA-N 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- JQYMGXZJTCOARG-UHFFFAOYSA-N Reactive blue 2 Chemical compound C1=2C(=O)C3=CC=CC=C3C(=O)C=2C(N)=C(S(O)(=O)=O)C=C1NC(C=C1S(O)(=O)=O)=CC=C1NC(N=1)=NC(Cl)=NC=1NC1=CC=CC(S(O)(=O)=O)=C1 JQYMGXZJTCOARG-UHFFFAOYSA-N 0.000 description 1
- 102000007312 Recombinant Proteins Human genes 0.000 description 1
- 108010033725 Recombinant Proteins Proteins 0.000 description 1
- GKBMIFPNPOSTHB-BJBKLNMKSA-N Recombinant soluble CD4 Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(O)=O GKBMIFPNPOSTHB-BJBKLNMKSA-N 0.000 description 1
- 210000002254 Renal Artery Anatomy 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010038428 Renal disease Diseases 0.000 description 1
- 206010038435 Renal failure Diseases 0.000 description 1
- 229920000970 Repeated sequence (DNA) Polymers 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- UJTZHGHXJKIAOS-WHFBIAKZSA-N Ser-Gln Chemical compound OC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O UJTZHGHXJKIAOS-WHFBIAKZSA-N 0.000 description 1
- WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical compound OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M Sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 208000008513 Spinal Cord Injury Diseases 0.000 description 1
- 108010026479 Src peptide Proteins 0.000 description 1
- 102100008904 TFRC Human genes 0.000 description 1
- 101000436695 TGFA Proteins 0.000 description 1
- 229960003604 Testosterone Drugs 0.000 description 1
- BIYXEUAFGLTAEM-WUJLRWPWSA-N Thr-Gly Chemical compound C[C@@H](O)[C@H](N)C(=O)NCC(O)=O BIYXEUAFGLTAEM-WUJLRWPWSA-N 0.000 description 1
- BQBCIBCLXBKYHW-CSMHCCOUSA-N Thr-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])[C@@H](C)O BQBCIBCLXBKYHW-CSMHCCOUSA-N 0.000 description 1
- DSGIVWSDDRDJIO-ZXXMMSQZSA-N Thr-Thr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O DSGIVWSDDRDJIO-ZXXMMSQZSA-N 0.000 description 1
- YKRQRPFODDJQTC-UHFFFAOYSA-N Threoninyl-Lysine Chemical compound CC(O)C(N)C(=O)NC(C(O)=O)CCCCN YKRQRPFODDJQTC-UHFFFAOYSA-N 0.000 description 1
- CKHWEVXPLJBEOZ-UHFFFAOYSA-N Threoninyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)C(C)O CKHWEVXPLJBEOZ-UHFFFAOYSA-N 0.000 description 1
- 102000036902 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine Kinase Proteins 0.000 description 1
- 229920001949 Transfer RNA Polymers 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- DZHDVYLBNKMLMB-ZFWWWQNUSA-N Trp-Lys Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 DZHDVYLBNKMLMB-ZFWWWQNUSA-N 0.000 description 1
- ZSXJENBJGRHKIG-UHFFFAOYSA-N Tyrosyl-Serine Chemical compound OCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 ZSXJENBJGRHKIG-UHFFFAOYSA-N 0.000 description 1
- MFEVVAXTBZELLL-UHFFFAOYSA-N Tyrosyl-Threonine Chemical compound CC(O)C(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 MFEVVAXTBZELLL-UHFFFAOYSA-N 0.000 description 1
- 210000002700 Urine Anatomy 0.000 description 1
- 208000007089 Vaccinia Diseases 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- UPJONISHZRADBH-XPUUQOCRSA-N Val-Glu Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O UPJONISHZRADBH-XPUUQOCRSA-N 0.000 description 1
- STTYIMSDIYISRG-WDSKDSINSA-N Val-Ser Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(O)=O STTYIMSDIYISRG-WDSKDSINSA-N 0.000 description 1
- 241000711975 Vesicular stomatitis virus Species 0.000 description 1
- 208000001756 Virus Disease Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 102000034433 acetylcholine receptors Human genes 0.000 description 1
- 108020000715 acetylcholine receptors Proteins 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000001166 ammonium sulphate Substances 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 201000000975 anemia of prematurity Diseases 0.000 description 1
- 230000003042 antagnostic Effects 0.000 description 1
- 230000003432 anti-folate Effects 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 108010062796 arginyllysine Proteins 0.000 description 1
- 108010027485 asialoerythropoietin Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 238000003556 assay method Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 208000005980 beta-Thalassemia Diseases 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000000711 cancerogenic Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229920002083 cellular DNA Polymers 0.000 description 1
- 230000005591 charge neutralization Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000014107 chromosome localization Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000005094 computer simulation Methods 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 230000001819 effect on gene Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 201000000523 end stage renal failure Diseases 0.000 description 1
- 230000002255 enzymatic Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000000267 erythroid cells Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001400 expression cloning Methods 0.000 description 1
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 102000018146 globin family Human genes 0.000 description 1
- 108060003196 globin family Proteins 0.000 description 1
- 102000005396 glutamine synthetase family Human genes 0.000 description 1
- 108020002326 glutamine synthetase family Proteins 0.000 description 1
- 108010078144 glutaminyl-glycine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000000025 haemostatic Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010211 hemagglutination inhibition (HI) assay Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- XKUUMWKWUZRRPD-UHFFFAOYSA-N heptan-2-amine;sulfuric acid Chemical compound [O-]S([O-])(=O)=O.CCCCCC(C)[NH3+].CCCCCC(C)[NH3+] XKUUMWKWUZRRPD-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal Effects 0.000 description 1
- 102000019638 human APOA1 protein Human genes 0.000 description 1
- 102000026806 human F8 protein Human genes 0.000 description 1
- 102000029624 human TGFA protein Human genes 0.000 description 1
- 229960000027 human factor IX Drugs 0.000 description 1
- 229960000900 human factor VIII Drugs 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 230000000222 hyperoxic Effects 0.000 description 1
- 230000001771 impaired Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000977 initiatory Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 238000009114 investigational therapy Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000011031 large scale production Methods 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 108010000761 leucylarginine Proteins 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 201000009673 liver disease Diseases 0.000 description 1
- 238000011068 load Methods 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 108010056582 methionylglutamic acid Proteins 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 230000001264 neutralization Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229920001894 non-coding RNA Polymers 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 238000010915 one-step procedure Methods 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005020 pharmaceutical industry Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 108010018625 phenylalanylarginine Proteins 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108091008117 polyclonal antibodies Proteins 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- OZAIFHULBGXAKX-UHFFFAOYSA-N precursor Substances N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000006870 primary polycythemia Diseases 0.000 description 1
- 230000001566 pro-viral Effects 0.000 description 1
- 238000011137 process chromatography Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 108010025826 prolyl-leucyl-arginine Proteins 0.000 description 1
- 108010077112 prolyl-proline Proteins 0.000 description 1
- 108010090894 prolylleucine Proteins 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000013595 protein glycosylation Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 239000002684 recombinant hormone Substances 0.000 description 1
- 108010043277 recombinant soluble CD4 Proteins 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001177 retroviral Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 239000000700 tracer Substances 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 108010078580 tyrosylleucine Proteins 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- IOUPEELXVYPCPG-UHFFFAOYSA-N val-gly Chemical compound CC(C)C(N)C(=O)NCC(O)=O IOUPEELXVYPCPG-UHFFFAOYSA-N 0.000 description 1
Abstract
The present invention relates to a method for obtaining high purity recombinant human EPO. The claimed process is characterized, furthermore, by avoiding exposing the protein to extreme temperature conditions and to organic solvents that could affect its biological activity or become toxic, its use in humans. The procedure consists of differential precipitation, hydrophobic interaction chromatography, concentration and diafiltration, successive anionic and cationic chromatography, new concentration and diafiltration and gel permeation chromatography. The procedure is distinguished by not using steps of high pressure liquid chromatography and by a high percentage of recovery of EPO. The invention also comprises the EPO obtained according to the procedure described
Description
PROCEDURE FOR ERITROPOYETINE PURIFICATION
HUMAN RECOMBINANT FROM SUPPORTING PARTIES
CULTIVATION OF CELLULES AND ERYTHROPOYETINAHUMANA
RECOMBINANT OBTAINED WITH SUCH PROCEDURE
Technical Description of the Invention A method for obtaining erythropoietin (EPO) characterized by a sequence of concatenated separation steps including differential precipitation, hydrophobic interaction liquid chromatography, liquid anion exchange chromatography, liquid cation exchange chromatography and liquid chromatography of molecular exclusion. The EPO obtained by the method described.
TECHNICAL FIELD OF THE INVENTION The present invention relates to a method for the purification of EPO.
STATE OF THE ART EPO is a glycoprotein that stimulates the differentiation of erythroblasts in the bone marrow, thereby increasing the number of erythrocytes in the blood. The average life of erythrocytes in humans is 120 days, for which a human being loses 1/120 of their erythrocytes every day.
This loss must be continuously replenished to keep the number of red blood cells stable.
The existence of the EPO was postulated from the beginning of the century and was definitely demonstrated by Reissman and Erslev in the early 50's. See Carnot, et al., C.R. Acad. Sci., (France), 143, 384-6 (1906); Carnot, et al., C.R. Acad. Sci., (France), 143, 432-5 (1906); Carnot, et al., C.R. Soc. Biol., 111, 344-6 (1906); Carnot, C.R. Soc. Biol., 111, 463-5 (1906); Reissman, Blood, 1950, 5, 372-80 (1950) and Erslev, Blood, 8, 349-57 (1953). The experiments of Reissman and Erslev were quickly confirmed by other researchers. See Hodgson, et al., Blood, 9, 299-309 (1954); Gordon, et al., Proc. Soc. Exp. Biol. Med., 86, 255-8 (1954) and Borsook, et al., Blood, 9, 734-42 (1954). The individualization of the production site sparked a great debate. Successive works led to identify the kidney as the main organ and peritubular interstitial cells as the producer synthesis site. See Jacobson, et al., Nature, 179, 633-4 (1957); Kuratowska, et al., Blood, 18, 527-34 (1961); Fisher, Acta Hematol., 26, 224-32 (1961); Fisher, et al., Nature, 205, 611-2 (1965); Frenkel, et al., Ann. N.Y. Acad. Sci., 149, 1, 292-3 (1968); Busuttil, et al., Proc. Soc. Exp. Biol. Med., 137, 1, 327-30 (1971); Busuttil, Acta Haematol., (Switzerland), 47, 4, 238-42 (1972); Erslev, Blood, 44, 1, 77-85 (1974); Kazal, Ann. Clin. Lab. Sci., 5, 2, 98-109 (1975); Sherwood, et al., Endocrinology, 99, 2, 504-10 (1976); Fisher, Ann. Rev. Pharmacol. Toxicol., 28, 101-22 (1988); Jelkmann, et al., Exp. Hematol., 11, 7, 581-8 (1983); Kurtz, et al., Proc. Natl. Acad. Sci., (USA), 80, 13, 4008-11 (1983); Caro, et al., J. Lab. Clin. Med., 103, 6, 922-31 (1984); Caro, et al., Exp. Hematol., 12, 357 (1984); Schuster, et al., Blood, 70, 1, 316-8 (1986); Bondurant, et al, Mol. Cell. Biol., 6, 7, 2731-3 (1986); Bondurant, et al., Mol. Cell. Biol., 6, 7, 2731-3 (1986); Schuster, et al., Blood, 71, 2, 524-7 (1988); Koury, et al., Blood, 71, 2, 524-7 (1988); Lacombe, et al., J. Clin. Invest., 81, 2, 620-3 (1988); Koury, et al., Blood, 74, 2, 645-51 (1989). A smaller proportion, from 10% to 15% of the total EPO is produced by the liver in adults. See Naughton, et al., J. Surg. Oncol., 12, 3, 227-42 (1979); Liu, et al., J. Surg. Oncol., 15, 2, 121-32 (1980); Dornfest, et al., Ann. Clin. Lab. Sci., 11, 1, 37-46 (1981); Dinkelaar, et al., Exp. Hematol., 9, 7, 796-803 (1981); Caro, et al., Am. J. Physiol., 244, 5 (1983); Dornfest, et al., J. Lab. Clin. Med., 102, 2, 274-85 (1983); Naughton, et al., Ann. Clin. Lab. Sci., 13, 5, 432-8 (1983); Jacobs, et al., Nature, 313, 6005, 806-10 (1985); Erslev, et al., Med. Oncol. Tumor. Pharmacother., 3, 3-4, 159-64 (1986). EPO is produced proportionally to the degree of tissue hypoxia, and its expression grows by increasing the number of producing cells. EPO is a protein that has shown great efficacy for the treatment of anemia caused by different factors, especially anemia of renal origin. However, its therapeutic availability was limited until recently by the lack of a mass production method, since the quantity and quality of the EPO obtained by any of the known extractive systems were insufficient. Recently, the use of recombinant DNA techniques has made it possible to obtain proteins in large quantities. The application of these techniques to eukaryotic cells has allowed the large-scale production of EPO. See US patents 5,688,679 (Powell), 5,547,933 (Lin), 5,756,349 (Lin), 4,703,008 (Lin) and 4,677,195 (Hewick et al.) Once productivity is assured, the next problem is the systems of separation of the EPO, fundamental to guarantee the purity necessary for its application in humans.
Currently there are several techniques for the separation of glycoproteins such as EPO. These techniques include ultrafiltration, electro-focusing on a column, electrophoresis on a flat bed, filtration using gels, electrophoresis, isotachophoresis and several other chromatographic methods. Among the most used chromatography techniques are the ion exchange method and the adsorption chromatography.
The ion exchange method is a separation technique by which the components of the solution are distinguished according to their differential load and isolated by elution, either stepwise or through the application of a continuous gradient, with eluents of varying strength ionic or pH. The method uses a gel or resin matrix, either positive or negative, to induce the sticking or electrostatic adsorption of the components of opposite charge. During desorption or elution the components of the sample are displaced from the resin by the ions present in the solution or buffer used to elute, or by a pH modification that alters the differential charge of the molecule of interest. Reverse phase adsorption chromatography involves the separation of the components of the sample according to their different polarities. The components of the sample are first adsorbed by a resin composed of a silica matrix coated with an organic polymer. Subsequently, when the displacement of the components is verified by non-polar molecules of the eluting solvent, either in stages or through the application of a continuous gradient, selective desorption of the sample is obtained. The separation techniques mentioned above were initially used in the separation of relatively small hydrophobic or hydrophilic molecules. Its application to the separation of larger molecules, such as proteins, and especially to complex proteins such as lipoproteins, nucleoproteins and glycoproteins, is more recent. Several publications illustrate the state of the art regarding the separation of proteins. See Sofer, et al., "Handbook of Process Chromatography", (Academic Press Inc., San Diego, California, 1997); Olson, Ed., "Separation Technology", (Interpharm Press, Inc., Buffalo Grove, Illinois, 1995); Franks, Ed., "Protein Biotechnology", (Humana Press, Totowa, New Jersey, 1993); Deutscher, Ed., "Guide to Protein Purification", Methods of Enzymology, Vol. 182 (Academic Press Inc., San Diego, California, 1991); Seetharam and Sharma, Eds., "Purification and Analysis of Recombinant Proteins", (Marcel Dekker, Inc., New York, New York, 1991); Harris and Angal, Eds., "Protein Purification Applications", (Oxford University Press, Oxford, England, 1990); Brown, et al., Anaytical Biochemistry, 99, 1-21 (1979); Harrison, et al., "VDYAC ™ Comprehensive Guide to Reverse Phase Materials for HPLC," pp. 1-12, (The Sep / A / Ra / Tions Groups, Hesperia, California, 1984). On the other hand, the non-polar solvents recommended or usually used for the separation of proteins and polypeptides by the reverse phase high pressure liquid chromatography technique include reagents, such as acetonitrile, difficult to remove from the protein involved and potentially toxic to the Humans. See Parsons, et al., Endocrinology, 114, 6, 2223-2227 (1984). It should be noted, however, that aqueous solutions of ethanol and formic acid have been used for the elution of proteins. See Takagaki, et al., Journal of Biological Chemistry, 5, 4, 1536-1541 (1980). Previously, hematopoietic factors of interest due to their therapeutic use in humans, such as EPO, thrombopoietin and granulocyte colony stimulating factor, were obtained from urinary sources. See Miyake, et al., Journal of Biological Chemistry, 252, 15, 5558-5564 (1979). The recovery of these proteins from urinary sources was characterized by their low yield, inadequate purity and high cost due to the low level of concentration in which these proteins naturally occur. The application of immunoaffinity chromatographies for the recovery of proteins by the use of monoclonal antibodies specific for the protein of interest is also known. Nevertheless, in the particular case of EPO, by inducing the change of the affinity constant of the monoclonal antibody for the protein to achieve its recovery, the biological activity of EPO is drastically reduced. Recently, several specific methods for the separation of recombinant EPO have been revealed. One of these methods consists in the recovery of the protein by anion exchange chromatography with selective protease removal, followed by reverse phase chromatography and filtration. See US patent 4,667,016 (Lai, et al.) This technique claims a 16% yield of EPO with unknown specific activity and purity. Another proposed method for the separation of recombinant EPO consists of the application of reverse phase high pressure liquid chromatography to a solution of the partially purified protein. See US patent 4,677,195 (Hewick, et al.) This method could not be reproduced in practice.
Description of the Invention Although there is a large amount of information regarding the production of recombinant human EPO, a purification method that results in an EPO suitable for use in humans, with a purity greater than 99% and with absence of contaminants such as: a) aggregate material, b) degraded material, c) spurious proteins and, d) proteases. A purity less than 99% or the presence of any of the mentioned contaminants can be toxic to humans. On the other hand, several of the methods proposed for the purification of EPO are not efficiently applicable on an industrial scale. Some of the known methods incorporate reverse phase high pressure liquid chromatography steps. This method requires, on the one hand, a greater investment in equipment and maintenance compared to other separation methods and, on the other hand, it uses organic solvents that make the purification process more expensive and that are also dangerous, difficult to handle and highly polluting. environment. Other proposed methods are irreproducible in practice or have low recovery of the protein.
The present invention describes an EPO purification system characterized by a high recovery, purity and quality of the protein obtained. An advantage of the method described in this patent is the obtaining of EPO free of proteases and of unwanted molecular variants such as aggregates, degraded and isoelectric point molecules different from the expected one, among others. The EPO obtained by the claimed method has more than 99% purity and can be used to formulate pharmaceutical compounds for use in humans without the need for subsequent purification treatments. The EPO obtained by the claimed process is a heterogeneous protein composed of not less than 5 and not more than 8 isoforms of isoelectric point comprised between 3.0 and 4.5 and possesses a specific biological activity in vivo of more than 100,000 IU / mg of protein measured by the presence of 59Fe in ex-hypoxic polycythaemic mice. Another advantage of the claimed invention is its reproducibility on an industrial scale and its low environmental impact. The claimed process is a clean process that does not use separation steps based on reverse phase high pressure liquid chromatography, nor does it use organic solvents that may be harmful to the environment. A further advantage of the invention is that it avoids subjecting EPO to extreme temperature conditions or exposing it to organic solvents or other solutions that may be aggressive to the protein or toxic for use in humans. The claimed method consists of several separation steps including differential precipitation of supernatants of EPO-containing cell cultures, concentration and diafiltration, and chromatographies by hydrophobic interaction, anion exchange, cation exchange, and molecular exclusion. The following examples illustrate the separation steps followed in the claimed method.
Example 1 Recovery (Clarification)
In 30 liters of sterile concentrate (See patent application AR-98-01-05611, of November 6, 1998), from culture supernatants of EPO-producing cells, which contained 10.7 g of EPO, 7,920 grams of ammonium sulphate. The solution is maintained at 4 ° C for 24 h. Several contaminating proteins precipitate while the EPO remains in solution. The product is centrifuged at 5,000 RPM, in a Sorvall brand centrifuge, using an HG4L rotor. This separation step yields 10.7 grams of EPO.
Example 2 Hydrophobic Interaction Chromatography
The material from the previous step is chromatographed using a hydrophobic interaction matrix (Phenyl Sepharose 6 Fast Flow low sub.- Pharmacia) according to the following parameters and conditions: 1. Equipment a. Pre-Column 1) Diameter: 10 cm 2) Bed height: 25 cm 3) Matrix a) Q-Sepharose Big Bead. (Pharmacia) b) Volume: 2, 000 ml b. Column 1) Diameter: 20 cm 2) Bed height: 13 cm 3) Matrix: a) Phenyl-Sepharose 6 Fast Flow low sub. (Pharmacia) b) Volume: 4,000 ml Solutions and Buffers a. Buffer A: NaH2PO4 anh. 10 mM, pH 7.2 b. BufFer F: NaH2P04 anh. 10 mM, (NH4) 2S04 1.8 M, pH 7.2 c. Buffer G: NaH2PO4 anh. 150 mM, pH 7.2 d. Isoprol 20% e. 0.5 N NaOH Material a Chromatograph a. Ammonium sulfate supernatant from the previous example b. Sample conditions 1) Volume: 30,000 ml 2) Total protein mass measured by Bradford test: 20-40 grams
3) Approximate concentration measured by Bradford test: 0.6-1.3 mg / ml
4) Conductivity: 190-210 mSi / cm 5) pH: 7.2 4. Sanitization and Balancing of the Pre-column (*) To balance the precolumn, the following solutions or bufFers are sequentially passed through it. the quantities detailed below: 1.0 ve (2 liters) of water; 1.0 ve (2 liters) of 0.5N NaOH; 1.0 ve (2 liters) of BufFer G and finally 1.5 ve (3 liters) of BufFer F. 5. Sanitizing and Balancing the Column (*) In order to balance the column, the following are sequentially passed through it: solutions or buffers in the quantities detailed below: 1.0 ve (4 liters) of water; 1.0 ve (4 liters) of 20% isopropanol; 1.0 ve (4 liters) of water, 1.0 ve (4 liters) of 0.5N NaOH; 1.0 ve (4 liters) of water; 1.0 ve (4 liters) of BufFer G and finally 1.5 ve (6 liters) of BufFer F. 6. Run Conditions Once the precolumn and the column are balanced, the second one is connected after the first one and the seed is sown. material to be chromatographed. Said seeding is carried out at a temperature of 4 ° C at a flow of 100 ml / min. The elution is then carried out at the same flow but at room temperature, passing the following solutions and bufFers in the order and quantities detailed below: 2.5 ve (10 liters) of BufFer F, (after this buffer the precolumn is removed). Once the precolumn is removed, the chromatographic run is continued on the Phenyl Sepharose column on which a gradient of BufFer F-Buffer A is made starting from an 85:15 ratio of said bufFers until reaching a 50:50 ratio of the same in a total volume of 10 ve (40 liters). At the end of the gradient, 1.5 ve (6 liters) of BufFer F-BufFer A are passed in a 30:70 ratio and finally 1.5 ve (6 liters) of water. The selected fractions, containing EPO, are sterilized by filtration through a 0.22 μm porous membrane and kept at 4 ° C. This separation step yields 7.5 grams of EPO. (*) see means column volume
Example 3 Concentration and Diafiltration
The fractions from the previous example are concentrated and diafiltered according to the following parameters and conditions: 1. Equipment a. Peristaltic pump: Watson Marlow - Cat. No. 302S b. Tubing: Masterflex - Cat. No. 06402-18 c. Concentrator: Prep Scale Millipore CDU F006LC 2. Solutions and BufFers a. Sodium dodecyl sulfate (SDS) 10 mM b. Triton X-100 lmM c. NaOH 0, lN d. Water e. BufFer A: NaH2PO4 anh. 10 mM, pH 7.2 3. Material to Process a. Selected fractions from the previous example b. Sample conditions 1) Volume: 7,000-10,000 ml 2) Conductivity: 170-130 mSi / cm 3) pH: 7.2 4. Procedure First, the cleaning, sanitization and equilibration of the equipment is carried out by passing through the same next sequence of solutions and bufFers: 10 liters of 10 mM SDS; 40 liters of water; 10 liters of Triton X-100 1 mM, 40 liters of water; 10 liters of NaOH 0. ÍN; 40 liters of water and finally 5 liters of BufFer A. In this way the equipment is able to be used to carry out the concentration and diafiltration process against BufFer A of the selected fractions, according to the current methodology. 5. Final Condition of Concentration a. Final volume of concentrate: 2,000 ml b. Diafiltered against: BufFer A c. Conductivity: 1,100-1,550 μSi / cm d. pH: 7.2 This separation step yields 7.2 grams of EPO.
Example 4 Anion Exchange Chromatography
The material from the previous example is chromatographed using an anion exchange matrix according to the following parameters and conditions: 1. Equipment a. Column 1) Diameter: 10 cm 2) Bed height: 25 cm 3) Matrix a) Q-Sepharose Fast Flow (Pharmacia) b) Volume: 2,000 ml Solutions and BufFers a. BufFer A: NaH2PO4 anh. 10 mM, pH 7.2 b. BufFer G: NaH2PO4 anh. 150 mM, pH 7.2 c. BufFer N: Ac. 50 mM acetic acid, 500 mM NaCl, pH 4.0 d. BufFer S: Ac. 50 mM acetic acid, pH 4.0 e. NaOH 0.5 N Material to Chromatograph a. Selected fractions of hydrophobic interaction, concentrated and diafiltered. b. Sample conditions 1) Volume: 2,000 ml 2) Total protein mass measured by Bradford test: 8.0-10 grams 3) Approximate concentration measured by Bradford test: 4.0-5.0 mg / ml
4) Conductivity: 1,100-1,550 μSi / cm 5) pH: 7.2 Sanitization and Balancing of the Column (*) In order to balance the column, the following solutions or bufFers are passed sequentially in the quantities They are detailed below: 1.0 ve (2 liters) of water; 1.0 ve (2 liters) of 0.5N NaOH; 1.0 ve (2 liters) of BufFer N; 2.0 ve (4 liters) of BufFer S; 3.0 ve (6 liters) of BufFer G; and finally 2.0 ve (4 liters) of BufFer A. 5. Corrida conditions (*) Once the column is balanced, the material is chromatographed. Said seeding is carried out at room temperature at a flow of 100 ml / min. The elution is then carried out at the same flow and temperature, passing the following solutions and bufFers in the order and quantities detailed below: 1.0 ve (2 liters) of BufFer A and 4.0 ve (8 liters) of BufFer S. Next a gradient of BufFer S-BufFer N is made starting from a 100: 0 ratio until reaching a 50:50 ratio of the same in a total volume of 1.5 ve (3 liters). At the end of the gradient, 1.5 ve (3 liters) of BufFer N are passed. The selected fractions, containing EPO, are sterilized by filtration through a 0.22 μm porous membrane and stored at 4 ° C. This separation step yields 5.9 grams of EPO. (*) see means column volume
Example 5 Cationic Exchange Chromatography
The material from the previous example is chromatographed using a cation exchange matrix according to the following parameters and conditions: 1. Equipment a. Column 1) Diameter: 10 cm 2) Bed height: 25 cm 3) Matrix a) SP-Sepharose Fast Flow. (Pharmacia) b) Volume: 2,000 ml Solutions and BufFers a. BufFer D: Na2HPO4.12H2O 12.5 mM, Ac. Cítrico.H2O 4 mM, pH 6.0 b. BufFer E: Na2HPO4.12H2O 12.5 mM, Ac. Cítrico.H2O 4 mM, NaCl 0.5M, pH 6.0 c. NaOH 0.5 N Material a Chromatograph a. Fraction selected in the previous example adjusted to pH 6.0 with Ce NaOH. and diluted to a conductivity of 4,800 μS / cm (conductivity equal to BufFer D-BufFerE 93.5: 6.5) b. Sample conditions 1) Volume: 5,000 ml 2) Total protein mass measured by Bradford test: 4.5-6.5 grams 3) Approximate concentration measured by Bradford test: 0.9-1.3 mg / ml
4) Conductivity: 4,800 μS / cm (Same as BufFer D-BufFer E in a ratio of 93.5: 6.5) 5) pH: 6.0 Sanitization and Balancing of the Column (*) To balance the column, proceed to pass through it, in sequentially, the following solutions or bufFers in the quantities detailed below: 1.0 ve (2 liters) of water; 1.0 ve (2 liters) of 0.5N NaOH; 1.0 ve (2 liters) of BufFer E and finally 1.5 ve (3 liters) of BufFer D-BufFer E in a ratio 93.5: 6.5 5. Run Conditions (*) Once the column is balanced, the material is chromatographed . Said seeding is carried out at room temperature at a flow of 100 ml / min. The elution is then carried out at the same flow and temperature, passing the following solutions and bufFers in the order and quantities detailed below: 1.5 ve (3 liters) of BufFer D-BufFer E in a 93.5: 6.5 ratio. Then a gradient of BufFer D-BufFer E is made starting from a 93.5: 6.5 ratio of said bufFer until reaching a 50:50 ratio of the same in a total volume of 2.0 ve (4 liters). At the end of the gradient 1.5 ve (3 liters) of BufFer E are passed. The selected fractions, containing EPO, are sterilized by filtration through a 0.22 mm porous membrane and stored at 4 ° C. This separation step yields 4.2 grams of EPO. (*) see means column volume
Example 6 Concentration and Diafiltration
The fractions from the previous example are concentrated and diafiltered according to the following parameters and conditions: 1. Equipment a. Peristaltic pump: Watson Marlow - Cat. No. 302S b. Tubing: Masterflex - Cat. No. 06402-18 c. Concentrator: Prep Scale Millipore CDU F002LC 2. Solutions and BufFers a. Sodium dodecyl sulfate (SDS) 10 mM b. Triton X-100 lmM c. NaOH 0, lN d. Water e. BufFer B: NaH2PO4 anh. 10 mM, 0.5 M NaCl, Lactose 0.05 mg ml, pH 7.2 Material to Process a. Fractions selected in the previous example b. Sample conditions 1) Volume: 8,000 mi 2) Total protein mass measured by Bradford test: 3.5-4.5 grams 3) Approximate concentration measured by Bradford test: 0.4-0.6 mg / ml
4) Conductivity: 5,000-8,000 μSi / cm 5) pH: 6.0 Procedure First, the equipment is cleaned, sanitized and balanced by passing the following sequence of solutions and buffeers: 10 liters of 10 mM SDS; 40 liters of water; 10 liters of Triton X-100 1 mM, 40 liters of water; 10 liters of 0.1N NaOH; 40 liters of water and finally 5 liters of BufFer B. In this way the equipment is able to be used to perform the concentration and diafiltration process against BufFer B of the selected fractions, according to the current methodology. Final Condition of Concentration a. Final volume of concentrate: 400 ml b. Diafiltered against: BufFer B c. Conductivity: 15,500-19,000 μSi / cm d. pH: 7.2 e. Conservation: at 4 ° C This separation step yields 4.0 grams of EPO.
Example 7 Molecular Exclusion Chromatography
The material from the previous step is chromatographed using a molecular exclusion matrix according to the following parameters and conditions: 1. Equipment a. Column 1) Diameter: 10 cm 2) Bed height: 76 cm 3) Matrix a) Sephacryl S-200 HP (Pharmacia) b) Volume: 6,000 ml 2. Solutions and BufFers a. Buffer B: NaH2PO4 anh. 10 mM, NaCl 0.15 M, Lactose 0.05 mg / ml, pH 7.2 b. NaOH 0.5 N 3. Material to Chromatograph a. Fractions selected in the previous example concentrated b. Sample conditions 1) Volume: 400 ml 2) Total protein mass measured by Bradford test: 3.5-4.5 grams 3) Approximate concentration measured by Bradford test: 8.5-11 mg / ml 4) Conductivity: 15.500-19.000 μSi / cm 5) pH: 7.2 4. Sanitization and Balancing of the Column (*) To balance the column, the following solutions or bufFers are passed sequentially in the quantities detailed below: 1.0 ve ( 6 liters) of water; 1.5 ve (9 liters) of 0.5N NaOH and finally 3.0 ve (18 liters) of Buffer B.
. Copying Conditions (*) Once the column is balanced, 100 ml of the material to be chromatographed is sown. Said seeding is carried out at room temperature at a flow of 35 ml / min. The elution is then carried out at the same flow and temperature, passing 0.75 ve (4.5 liters) of BufFer B. This procedure is repeated 4 times, that is, until the material to be chromatographed is finished. The selected fractions, containing EPO, are sterilized by filtration through a 0.22 μm porous membrane and stored at 4 ° C. This separation step yields 3.2 grams of EPO with 99% purity. (*) ve means column volume The previous step concludes the purification process obtaining recombinant human EPO with a degree of purity higher than 99% and with an overall process yield of approximately 30% following the sequence claimed in claim 2. A sample of the EPO obtained using the process described was submitted to the following analyzes to demonstrate its identity and purity:
In a denaturing polyacrylamide gel (SDS-PAGE) the purified EPO observed a broad band of more than 30 kDa molecular weight. See Fig. 1. The purified EPO was recognized by a monoclonal antibody as well as by a polyclonal antibody against human EPO in a "Western Blot" assay. See Fig. 2. The glycanase treatment of the purified EPO proved the existence of the glycosidic chains in quantity and molecular weight according to what was expected for EPO. See Fig. 3. The purified EPO showed to be composed of a series of isoelectric point species or isoforms between 3.0 and 4.5. See Fig. 4. The complete amino acid sequencing of purified EPO showed complete homology with natural human EPO having the following sequence of 165 amino acids, SEQ ID No. 1.
NH2 - -Ala Pro Pro Arg Leu He Cys Asp Ser Arg Val Leu Glu Arg Tyr Leu Leu Glu Wing Lys Glu Wing Glu Asn lie Thr Thr Gly Cys Wing Glu Hys Cys Ser Leu Asn Glu Asn He Thr Val Pro Asp Thr Lys Val Asn Phe Tyr Wing Trp Lys Arg Met Glu Val Gly Gln Gln Wing Val Glu Val Trp Gln Gly Leu Wing Leu Leu Ser Glu Wing Val Leu Arg Gly Gln Wing Leu Leu Val Asn Being Ser Gln Pro Trp Glu Pro Leu Gln Leu Hys Val Asp Lys Wing Val Ser Gly Leu Arg Ser Leu Thr Thr Leu Leu jArg Wing Ala Leu Gly Wing Gln Lys Glu Ala lie Ser Pro Pro Asp Wing Wing Wing Wing Pro Leu Arg Thr He Thr Wing Asp Thr Phe Arg Lys Leu Phe Arg Val Tyr Ser Asn Phe Leu Arg Gly Lys Leu Lys Leu Tyr Thr Gly Glu Wing Cys Arg Thr Gly Asp- COOH
X glycosylation sites
The presence of the four glycosylation sites on the 165 amino acid chain, as well as the complex structure of carbohydrates, and fundamentally the terminal sialic acid residues, were demonstrated together with their correct biological activity in vivo, in the test model of the ex-hypoxic polycythemic mouse, exhibiting total parallelism with the international standard co-subject. A sample of the EPO obtained by the described procedure was subjected to a reverse phase high-pressure liquid chromatography and molecular exclusion analysis. In both cases, a purity greater than 99% was demonstrated. See Figs. 5 and 6.
The following table illustrates the recovery of each separation step of the claimed process.
The following table illustrates the cumulative recovery of the procedure claimed in claim 2.
Description of Diagrams Fig. 1 illustrates an analysis by polyacrylamide gel electrophoresis (SDS-PAGE) of a sample of pure EPO, obtained according to the method described. Molecular weight markers are shown on lanes 1, 4 and 7. In streets 2, 3, 5 and 6, different masses of pure EPO obtained according to the claimed process were run. The purity of the obtained product and its apparent molecular weight of more than 30 kDa can be appreciated, which coincides with that of human urine EPO. Fig. 2 illustrates a "Western Blot" analysis of an EPO sample obtained according to the method described. The identity of the purified EPO is verified, since it is recognized by a human anti-EPO antibody. In Street 1, a human EPO standard was run, in the street 2 molecular weight markers and in the streets 3 to 5 EPO samples obtained according to the claimed method. Fig. 3 illustrates an SDS-PAGE analysis of a pure EPO sample obtained according to the described method, treated with glycanase. Molecular weight markers were run on streets 1, 4 and 8. On streets 2 and 7, untreated EPO is seen. In street 3, EPO treated with O-glycanase was run; the presence of an O-glycosylation is verified. In lane 5, partially degraded EPO was run with N-glycanase; the presence of 3 N-glycosylations with the molecular weights corresponding to those expected for EPO is verified. In lane 6, degraded EPO was run with O-glycanase and N-glycanase, obtaining the expected molecular weight for the fully deglycosylated protein. Fig. 4 illustrates a study of the isoelectric points of pure EPO samples produced according to the described method. The EPO samples were run in streets 2, 3 and 4, the isoelectric point markers in lanes 1 and 5. The presence of the forms corresponding to EPO, with isoelectric points between 3.0 and 4.5 is verified .
Fig. 5 reveals the purity of an EPO sample produced according to the method described using reverse phase high pressure liquid chromatography. Fig. 6 discloses the purity of an EPO sample produced according to the method described using high-pressure liquid chromatography for molecular exclusion.
Additional references
Adamson, "Epoetin Alfa: Into the New Millenium", Semin. One, 3 (7): 76-79 (June 25, 1998)
Alt et al., "Selective Multiplication of Dihydrofolate Reductase Genes in Methotrexate-resistant Variants of Cultured Murine Cells", J. Biol. Chem., 253: 1357-1370 (1978)
Anderson et al., "Erythropoietin for the Treatment of Porphyria Cutaneous Late in a Patient on Long-Term Hemodialysis" N. England J. of Med., 322 (5): 315-317 (1990)
Annable et al., "The Second International Reference Preparation of Erythropoietin, Human, Urinary, for Bioassay", Bull Wld. Hlth. Org., 47: 99-112 (1972)
Baciu et al., "Erythropoietin Interaction with the Mature Red Cell Membrane", Ann. N.Y. Acad. Sci., 414, 66-72 (1983)
Banerji et al., "Expression of a -Globin Gene is Enhanced by Remote SV40 DNA Sequences Cell", (part i) 27: 299-308 (1981)
Barthomeuf et al., "L'EPO Recombinante", Biofutur, 155: 16 (1996)
Battersby et al., "Isoforms of Recombinant Human Erythropoietin", Pathophysiology and Pharmacology of Erythropoietin. Springer-Verlag (1992) Begin, "Prediction Response to Treatment with Recombinant Human Erythropoetin in Anaemia Associated with Cancer", Med. Oncol., 15 (Suppl. 1): 38-46 (1998)
Benoist et al., "In Vivo Sequence Requirements of the SV40 Early Promoter Region," Nature, 290: 304-310 (1981)
Benton et al., "Screening .lambda.gt Recombinant Clones by Hybridization to Single Plaques in Situ", Science, 196, 180-182 (Apr. 8, 1977)
Benz et al., "Hemoglobin Switching in Sheep", J. Biol. Chem., 5025-5032 (1978)
Berk et al., "Sizing and Mapping of Early Adenoviruses mRNAs by Gel Electrophoresis of SI Endonuclease-Digested Hybrids", Cell, 12: 721-732 (1977)
Billat et al., "In Vitro and In Vivo Regulation of Hepatic Erythropoiesis by Erythropoietin and Glucocorticoids in the Rat Fetus", Exp. Hematol., 10 (1), 133-140 (1982)
Bos et al., "Eukaryotic Expression of Cloned cDNA Coding for Viral Influenza Glycoproteins Using an SV40 Vector: Use of Recombinant DNA Mutants to Study Structure-Function Relationships.sup.l" Proc. Symp. Mol. Biol. Negat, Strand Viruses Meeting, pp. 125-130, Compans et al., Eds., Academic Press, San Diego, California (1984)
Bostock et al., "Gene Amplification in Methotrexate-resistant Mouse Cells", Mol. Biol., 153: 219-236 (1981)
Brandan, et al., "In Vitro Assay of Erythropoietin in Fetal Mouse Liver Cultures 1. Comparison of Radioactive Tracers and Evidence of Assay Specificity," British J. Hematol., 47: 461-468 (1981)
Bray et al., "Human cDNA Clones for Four Species of G alpha. -signal Transduction Protein", P.N.AS. (USA), 83, 8893-8897 (Dec. 1986)
Breslow et al., "Isolation and Characterization of cDNA Clones for Human Apolipoprotein A-I", P.N.AS. (USA), 79, 6861-6865 (Nov. 1982)
Brown et al., "Relation of Amplified Dihydrofolate Reductase Genes to Double Minute Chromosomes in Unstably Resistant Mouse Fibroblast Cell Lines", Mol. Cell. Biol., 1 (12): 1077-1083 (1981)
Browne et al, "Erythropoietin: Gene Cloning, Protein Structure, and Biological Properties", Cold Spring Harbor Symposia on Quantitative Biology, Ll, 693-702 (1986)
Camiscoli et al., "Comparative Assay of Erythropoietin Standards", Ann. N.Y. Acad. Sci., 149: 40-45 (1968)
Canaani et al, "Regulated Expression of Human Interferon .beta.1 Gene after Transduction into Cultured Mouse and Rabbit Cells", P.N.A.S. (USA), 79, 5166-5170 (Sep. 1982)
Canadian Erythropoietin Study Group, "Association between Recombinant Human Erythropoietin and Quality of Life and Exercise Capacity of Patients Receiving Haemodialysis", BMJ, 300 (3): 573-578 (1990)
Casadevall, "Treatment of Anaemia with RHuEPO in Patients with MDS", Med. Oncol., 15 (Suppl. 1): 35-47 (1998)
Cazzola, "How and When to Use Erithropoietin", Curr. Op. Hetmatol, 5 (2): 103-108 (Mar. 1998)
Chan et al., "Construction and Selection of Recombinant Plasmids Containing Full-length Complementary DNAs Copesponding to Rat Insulins I and II", P.N.A.S. (USA), 76 (10), 5036-5040 (Oct. 1979)
Chernajovsky et al, "Efficient Constitutive Production of Human Fibroblast Interferon by Hámster Cells Transformed with the IFN Gene Fused to an SV40 Early Promoter", DNA, 3: 297-308 (1982)
Chapman et al, "Amplification and Hormone-regulated Expression of a Mouse Mammary Tumor Virus-Eco gpt Fusion Plasmid in Mouse 3T6 Cells", Mol. Cell. Biol., 3: 1421-1429 (1983) Chasin et al., "Mutant Alieles for Hypoxanthine Phosphoribosyltransferase: Codominant Expression, Complementation and Segregation in Hybrid Chínese Hamster Cells", Somatic Cell Genetics, 453-467 (1976)
Chen et al., "The Primary Structure and Genetic Organization of the Bovine Papiavirus Type 1 Genome", Nature, 299: 529-534 (1982)
Chiba et al., "Stabilization of Urinary Erythropoietin", Biochem. Biophys. Res. Commun., 47 (6), 1372-1377 (1972)
Choo et al, "Molecular Cloning of the Gene for Human Anti-Haemophilic Factor IX", Nature, 299, 178-180 (Sep. 9, 1982)
Choppin et al, "Characterization of Erythropoietin Produced by IW32 Murine Erythroleukemia Cells", Blood, 64 (2), 341-347 (Aug. 1984)
Christman et al., "Amplification of Expression of Hepatitis B Surface Antigen in 3T3 Cells Cotransfected with a Dominant-acting Gene and Cloned Viral DNA", P.N.A.S. 79, 1815-1819 (Mar. 1982)
Claus-Walker et al., "Spinal Cord Injury and Serum Erythropoietin", Arch. Phys. Med. Rehabil, 65, 370-374 (Jui. 1984) Colby et al., "Immunological Differentiation Between E. Coli and CHO Cell- Derived Recombinant and Natural Human .beta.-Interferons.sup.l ", J. Immunol, 133 (6), 3091-3095 (1984)
Collen et al., "Biological Properties of Human Tissue-Type Plasminogen Activator Obtained by Expression of Recombinant DNA in Mammalian Cells", J. of Pharmacology and Exp. Therapeutics, 231 (1), 146-152 (1984)
Colman, "Cells That Secret Foreign Proteins," TIBS, 435-437 (Dec. 1982)
Congote et al., "Isolation of Two Biologically Active Peptides, Erythrotropin I and Erythrotropin II from Fetal Calf Intestine", Biochem. Biophys. Res. Comm., 115 (2), 477-483 (Sep. 15, 1983)
Congote et al, "The Erythrotropins, New Erythroid Cell Stimulating Factors Extracted from Human and Bovine Fetal Tissues," Abstract 364, Proceedings 7th International Congress of Endocrinology, (Quebec City, Quebec, June 1-7, 1984)
Congote, "High Performance Liquid Chromatographic Separation of Serum Erythrotropin and Erythropoietin", Chromatography, 310: 396-400 (1984)
Contrera et al., "Extraction of Erythropoietin from Kidneys of Hypoxic and Phenylhydrazine-treated Rats", Blood, 25 (5), 809-816 (May 1965)
Corees et al, "Integration, Transcription and Control of a Drosophila Heat Shock Gene in Mouse Cells", Proc. Nati Acad. Sci. (USA), 78 (11): 7038-7042 (1981)
Corden et al., "Promoter Sequences of Eukaryotic Protein-coding Genes", Science, 209: 1406-1414 (1980)
Costantini et al., "Gene Transfer into the Mouse Germ-Line", J. Cell Physiol. Supp. 1, 219-226 (1982)
Cotes et al, "Changes in Serum Immunoreactive Erythropoietin during the Menstrual Cycle and Normal Pregnancy," Brit. J. Obstet. Gynaecol, 90, 304-311 (Apr. 1983)
Cotes et al., "Bio-Assay of Erythropoietin in Mice Made Polycythaemic by Exposure to Air at Reduced Pressure", Nature, 191, 1065-1067 (Sep. 9, 1961)
Cotes, "Erythropoietin" Chapter: "Physiological Studies of Erythropoietin in Plasma", Jelkman and Gross Eds., 57-79 (1990)
Crouse et al., "Expression and Amplification of Engineered Mouse Dihydrofolate Reductase Minigenes", Mol. Cell. Biol., 3: 257-266 (1983)
Craig Crowley et al, "Plasmid-directed Synthesis of Hepatitis B Surface Antigen in Monkey Cells", Mol. Cell. Biol, 3: 44-55 (1983) Dainiak et al., "Mechanisms of Abnormal Erytropoiesis in Malignancy", Cancer, 51 (6), 1101-1106 (1983)
Danko et al., "Epoetin Alfa, for Treatment of Postpartum Anaemia", The Lancet, 334: 737-738 (1990)
Das et al., "Use of Synthetic Oligonucleotide Probes Complementary to Genes for Human HLA-DR.alpha. And .beta, as Extension Primers for the Isolation of 5 '-specific Genomic Clones", P.N.A.S. (USA) 80, 1531-1535 (Mar. 1983)
Davis et al. "A Manual for Genetic Engineering, Advanced Bacterial Genetics," Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, pp. 55-58, 174-176 (1983)
Davis et al., "Active Influenza Virus Neuraminidase is Expressed in Monkey Cells from cDNA Cloned in Simian Virus 40 Vectors", Proc. Nati Acad. Sci. (USA), 80, 3976-3980 (1983)
Davis et al, "Characterization of Recombinant Human Erythropoietin Produced in Chínese Hamster Ovary Cells," Biochem 26: 2633-2638 (1987)
De Saint Vincent et al, "The Cloning and Reintroduction into Animal Cells of a Functional CAD Gene, a Dominant Amplifiable Genetic Marker", Cell, 27: 267-277 (1981)
DeGowin et al, "The Mouse with Hypoxia-induced Erythremie, an Erythropoietin Bioassay Animal", J. Lab. Clin. Med. 60 (5): 846-852 (1962)
Derynck et al, "Human Transforming Growth Factor - alpha: Precursor Structure and Expression in E. Coli", Cell, 38, 287-297 (Aug. 1984)
Dessypris et al., "Effect of Purée Erythropoietin on DNA-synthesis by Human Mapow Day 15 Erythroid Burst Forming Units in Short-term Liquid Culture", Brit. J. Haematol., 56, 295-306 (1984)
Devos et al, "Purification of Recombinant Glycosylated Human Gamma Interferon Expressed in Transformed Chínese Hamster Ovary Cells", Interferon Research, 4, 461-468 (1984)
DiMaio et al., "Bovine Papillomavirus Vector that Propagates as a Plasmid in Both Mouse and Bacterial Cells", Proc. Natl. Acad. Sci., 79: 4030-4034 (1982)
DiMaio et al, "High-level Expression of a Cloned HLA Heavy Chain Gene Introduced Into Mouse Cells on a Bovine Papillomavirus Vector", Mol. Cell. Biol., 4: 340-350 (1984)
Dolnick et al., "Copelation of Dihydrofolate Reductase Elevation with Gene Amplification in a Homogeneously Staining Chromosomal Region in L5178Y Cells", J. Cell Biol., 83: 394-402 (1979)
Dordal et al, "Function and Composition of the Carbohydrate Portion of Human Urinary Erythropoietin", Experimental Hematology, 10, Supp. 11, p. 133, Abstract No. 222 (1982)
Dordal et al., "The Role of Carbohydrate in Erythropoietin Action", Endocrinology, 116 (6), 2293-2299 (1985)
Draganac et al. "Rapid Preparation of Human Urinary Erythropoietin by High Performance Liquid Chromatography", Exptal. Hematol, l l (Suppl 14): 58 (1983)
Dubé et al., "Glycosilation at Specific Sites of Erythropoietin is Essential for Biosynthesis, Secretion, and Biological Function", J. of Biol. Chem., 263 (33): 17516-16521 (1988)
Dubois et al, "The Development of Indications for the Preoperative Use of Recombinant Erythropoietin", Canc. J. Surg., 41 (5): 351-365 (1998)
Dukes et al., "Erythropoietin: a Complex with DifFerent In Vivo and In Vitro Activities", J. Lab. & Clin. Med. 76 (3): 439-444 (1970)
Dunn et al, "Use of a Computer Model in the Understanding of Erythropoietic Control Mechanisms", Chemical Abstracts, 91, 190417r (1979)
Dunn et al, "Cupent Concepts in Erythropoiesis", John Wiley & Sons, Chichester, England, (1983) Dunn et al., "Serum Erythropoietin Titers during Prolonged Bedrest; Relevance to the Anaemia of Space Flight", Eur. J. Appln. Physiol., 52, 178-182 (1984)
Dunn et al., "Erythropoietin Bioassays Using Fetal Mouse Liver Cells: Validations and Technical Improvements", Exp. Hematol., 11 (7), 590-600 (Aug. 1983)
Edman et al., "A Protein Sequentator", Eur. J. Biochem. 1, 80-91 (1967)
Eider et al, "Simian Virus 40 as an Eukaryotic Cloning Vehicle", Ann. Rev. Genet., 15: 295-340 (1981)
Edmunds et al., "Blood Pressure and Erythropoietin", The Lancet, 351-2 (February 13, 1988)
Emmanouel et al., "Metabolism of Pure Human Erythropoietin in the Rat", Am. J. Physiol, 247 (1 Pt 2), F168-76 (1984)
Ersley, "Erythropoietin Coming of Age", N. England J. of Med. 316 (2): 101-103 (1987)
Eschbach et al., "Correction by Erythropoietin (EPO) Therapy of the Anemia of Chronic Renal Failure (CRP) in Sheep", Clin. Res. 29 (2), 518A (1981)
Eschbach et al., "The Anemia of Chronic Kidney Failure in Sheep", J. Clin. Invest., 74 (2), 434-441 (Aug. 1984) Eschbach et al, "Correction of the Anemia of End-stage Renal Disease with Recombinant Human Er thropoietin", N. England J. of Med. 316 (2): 73-78 (1987)
Eschbach et al., "Recombinant Human Erythropoietin: Implications for Nephrology", Am. J. of Kidney Diseases XI (3): 203-209 (1988)
Eschbach, "The Anemia of Chronic Kidney Failure: Pathophysiology and the Effects of Recombinant Erythropoietin", Kidney Int., 35: 134-148 (1989)
Espada et al, "A New Method for Concentration of Erythropoietin from Human Uriñe", Biochemical Medicine, 3: 475-484 (1970)
Espada et al., "Purification of Human Urinary Erythropoietin", Acta Physiol. Latinoamer., 20: 122-129 (1970)
Espada et al, "Purification of Human Urinary Erythropoietin", Fed. Proc., 41, 1159 (1982)
Farber et al., "Translation of mRNA from Human Kidneys into Biologically Active Erythropoietin Following M? Croinjection into Xenopus Laevis Oocytes", J. Lab. Clin. Med., 102, 681 abstract (Nov. 1983)
Farber et al, "Translation of mRNA from Anemic Baboon Kidney into Biologically Active Erythropoietin", Exp. Hematol., 11, Supp. 14, Abstract 101 (1983) Farber, "Translation of RNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into Xenopus Laevis Oocytes", Clin. Res., 31 (4), 769A (Nov. 1983)
Farber et al., "Translation of mRNA from Human Kidneys into Biologically Active Erythropoietin Following Microinjection into Xenopus Laevis Oocytes", Blood, 62 (5), Supp. No. 1, Abstract 392, 122a (1983)
Fauld et al, "Epoetin (Recombinant Human Erythropoietin)", Drugs, 38 (6): 864-899 (1989)
Fiers et al, "The Human Firbroblast and Human Immune Interferon Genes and Their Expression in Homologous and Heterologous Cells", Phil. Trans. R. Soc. Lond., B299, 29-38 (1982)
Finch, "Erythropoiesis, Erythropoietin, and Iron", Blood, 60 (6), 1241-1246 (Dec. 1982)
Firkin, "Recombinant Human Erythropoietin Enters the Pharmacopeia", Aust. N.Z. J. Med. 19: 279-280 (1989)
Fisher et al., "Cooperative Erythropoietic Assay of Several Steroid Metabolites in Polycythemic Mee", Steroids, 30 (6), 833-845 (Dec. 1977)
Fisher, "Erythropoietin: Pharmacology, Biogenesis and Control of Production", Pharmacological Review, 24 (3), 459-508 (1972) Fisher, "Control of Erythropoietin Production", Proc. Soc. Exp. Biol. & Med., 173, 289-305 (1983)
Fisher et al, "Effects of Testosterone, Cobait &Hypoxia on Erythropoietin Production in the Isolated Perfused Dog Kidney," Ann. N.Y. Acad. Sci., 75-87 (1967)
Flaharty et al., "Epoetin: Human Recombinant Erythropoietin", Clin. Phar., 8: 769-782 (1989)
Flaharty et al., "Pharmacokinetics and Erythropoietic Response to Human Recombinant Erythropoietin in Healthy Men", Clin. Pharmacol. Ther., 47 (5): 557-564 (1990)
Food and Drug Administration, Department of Health and Human Services, Office of Biological Research and Review Center for Drugs and Biologics, "Points to Consider in the Production and Testing of New Drugs and Biologicals produced by Recombinant DNA Technology (April 10, 1985)
Fukuda et al, "Survival of Recombinant Erythropoietin in the Circulation: The Role of Carbohydrates", Blood, 73 (1) 84-89 (1989)
García et al, "Radioimmunoassay of Erythropoietin: Circulating Levéis in Normal and Polycythemic Human Beings", J. Lab. Clin. Med., 99, 624-635 (May 1982)
García et al., "Radioimmunoassay of Erythropoietin", Blood Cells, 5, 405-419 (1979) García et al., "Immunological Neutralization of Various Erythropoietins", Proc. Soc. Exptl. Biol. Med., 112, 712-714 (1963)
García, "The Radioimmunoassay of Human Plasma Erythropoietin", First International Conference on Hematopoiesis, Regulation of Erythropoiesis (Milan) 1972, 132-155
Gasser et al., "Expression of Abbreviated Mouse Dihydrofolate Reductase Genes in Cultured Hamster Cells", P.N.A.S. (USA), 79, 6522-6526 (Nov. 1982)
Gene Screen, New England Nuclear, Catalog No. NEF-972.
Gething et al., "Comparison of Different Eukaryotic Vectors for the Expression of Hemagglutinin Glycroprotein of Influenza Virus", Modern Approaches to Vaccines, pp. 263-268, Chanock et al., Eds. Cold Spring Harbor Lab (1984)
Gething et al, "Cell Surface Expression of Haemagglutinin Influenza from a Cloned DNA Copy of the RNA Gene", Nature, 293: 620-625 (1981)
Gething et al, "Construction of Haemagglutin Influenza Genes that Code for Intracellular and Secrete Forms of the Protein", Nature, 300,598-603 (Dec. 16, 1982)
Ghosh et al., "Identification of a Promoter Component Involved in Positioning of the 5'termini of Simian Virus 40 Early mRNAs", Proc. Natl. Acad. Sci., 78: 100-104 (1981) Gibson et al, "An Evaluation of Serum Erythropoietin Estimation by a Hemagglutination Inhibition Assay in the Differential Diagnosis of Polycythemia", Pathology, 16, 155-156 (Apr. 1984)
Gluzman, "SV40-Transformed Simian Cells Support the Replication of Early SV40 Mutants", Cell, 23, 175-182 (Jan. 1981)
Goeddel et al., "Synthesis of Human Fibroblast Interferon by E. Coli", Nucleic Acids Res., 8 (18), 4057-4074 (1980).
Goeddel et al., "Human Leukocyte Interferon Produced by E. Coli is Biologically Active", Nature, 287: 411-416 (Oct. 2, 1980)
Goldberg et al., "Regulation of the Erythropoietin Gene: Evidence that the Oxygen Sensor is a Heme Protein", Science, 242: 1412-1415 (1988)
Goldberg et al, "The Regulated Expression of Erythropoietin by Two Human Hepatoma Cell Lines", Proc. Natl. Acad. Sci. (USA), 84: 7972-7976 (1987)
Goldwasser et al, "Erythropoietin: Assay and Study of Its Mode of Action", Meth. in Enzymol., 37, 109-121 (1975)
Goldwasser, "From Protein to Gene to Protein: The Molecular Biology of Erythropoietin", Am. J.
of Kidney Diseases, 18 (4) Supp. 1, 10-13 (Oct. 1991)
Goldwasser, "Biochemical Control of Erythroid Development", Cupent Topics in Developmental Biology, A. Monroy and A.A. Noscona, Eds., 173-211, Academic Press, New York, New York (1966)
Goldwasser et al, "The Molecular Weight of Sheep Plasma Erythropoietin", J. of Biol. Chem., 247 (16), 5159-60 (Aug. 25, 1972)
Goldwasser et al, "Progress in the Purification of Erythropoietin," Ann. N.Y. Acad. Sci., 149: 49-53 (1968)
Goldwasser et al, "Part II, Chemistry and Purification of Erythropoietin", Ann. N.Y. Acad. Sci., 149: 49-53 (1968)
Goldwasser et al., "On the Mechanism of Erythropoietin-induced DifFerentiation", J. of Biol. Chem., 249 (13), 4202-4206 (June 10, 1974)
Goldwasser et al., "Purification of Erythropoietin", P.N.A.S. (USA), 68 (4), 697-698 (Apr. 1971)
Goldwasser et al., "On the Purification of Sheep Plasma Erythropoietin", Erythropoiesis, 43-49 (1962) Goldwasser et al., "Further Purification of Sheep Plasma Erythropoietin", Bioch. Biophys. Acta, 64, 487-496 (1962)
Goldwasser, "Some Thoughts on the Nature of Erythropoietin-Responsive Cells," J. Cell Physiol., 110 (Supp.1), 133-135 (1982)
Goldwasser et al., "An Assay for Erythropoietin In Vitro at the Milliunit Level", Endocrinology, 97 (2), 315-323 (Aug. 1975)
Goldwasser et al., "Erythropoietin and the Differentiation of Red Blood Cells," Fed. Proc. 34, 2285-2292 (Dec. 1975)
Goochee et al., "Enviromental Effects on Protein Glycosylation", Biotechnology, 8, 421-427 (May 1990)
Goochee et al., "The Oligosaccharides of Glycoproteins: Bioprocess Factors Affecting Oligosaccharide Structure and their Effect on Glycoprotein Properties", Biotechnology, 9, 1347-1555 (Dec. 1991)
Goodman et al, "Cloning of Homone Genes from a Mixture of cDNA Molecules", Meth. in Enzymol, 68, 75-90 (1979)
Goodnough et al., "Increased Preoperative Collection of Autologous Blood with Recombinant Human Erythropoietin Therapy", N. England J. of Med., 321 (17) (1989)
Goodnough, "The Use of Erythropoietin in the Enhancement of Autologous Tranfusion Therapy", Curr. Opin. Hematol., 2 (3): 214-218 (1995)
Goeddel, "Human Leukocyte Interferon Produced by E. Coli is Biologically Active", Nature, 287: 411-416 (1980)
Gordon et al., "A Plasma Extract with Erythropoietic Activity", Proc. Soc. Expt. Biol. Med., 86: 255-258 (1954)
Gorman C, et al., "High Efficiency DNA-mediated Transformation of Primate Cells", Science, 221: 551-553 (1983)
Gorman et al., "Expression of Recombinant Plasmids in Mammalian Cells Is Enhanced by Sodium Butyrate", Nucí. Acid Res., 11: 7631-7648 (1983)
Goto et al, "Production of Recombinant Human Erythropoietin in Mammalian Cells: Host-Cell Dependency of the Biological Activity of the Cloned Glycoprotein", Bio / Tech. 6, 67-71 (Jan. 1988)
Gough et al, "Molecular Cloning of cDNA Encoding to Murine Haematopoietic Growth Regulator, Granulocyte-Macrophage Colony Stimulating Factor", Nature, 309, 763-767 (1984) Gray et al., "Expression of Human Immune Interferon cDNA in E. Coli and Monkey Cells ", Nature, 295, 503-508 (Feb. 11, 1982)
Green et al, "Conserved Primary Sequences of the DNA Terminal Proteins of Five Different Human Adenoviruses Groups", Proc. Natl. Acad. Sci. (USA), 76 (9): 4380-4384 (1979)
Grundmann et al., "Characterization of cDNA Coding for Human Factor Xllla", P.N.A.S. (USA), 83, 8024-8028 (Nov. 1986)
Grunstein et al, "Colony Hybridization", Meth. in Enzym. 68, 379-389 (1979)
Grunstein et al., "Colony Hybridization: A Method for the Isolation of Cloned DNAs that Contain a Specific Gene", P.N.A.S. (USA), 72 (10), 3961-3965 (Oct. 1975)
Gruss et al., "Expression of Simian Virus 40-mouse Preproinsulin Recombinant in Monkey Kidney Cells Use of Preproinsulin RNA Processing Signáis", Proc. Natl. Acad. Sci. (USA), 78: 133-137 (1981)
Gruss et al., "Simian Virus 40 Tandem Repeated Sequences as an Element of the Early Romoter", Proc. Nati Acad. Sci. (USA), 78: 943-947 (1981)
Gubler et al., "A Simple and Very Efficient Method for Generating cDNA Libraries", Gene, 25, 263-269 (1983) Gurney et al., "Studies on Erythropoiesis, VI Erythropoietin in Human Plasma", J. Lab. & Clin. Med., 50 (4): 534-542 (1957)
Haddy, "Erythropoietin is Sickle Cell Disease", Am. Jour. Ped. Hematol./Oncol, 4 (2), 191-196 (Summer 1982)
Do et al, "Plasma Erythropoietin Concentrations During the Early Anemia of Prematurity", Acta. Pediatr. Scand., 72, 827-831 (1983)
Hagiwara et al., "Erythropoietin Production in a Primary Culture of Human Renal Carcinoma Cells Maintained in Nude Mice", Blood, 63 (4), 828-835 (Apr. 1984)
Hambley et al., "Erythropoietin: an Old Friend Revisited," BMJ, 300: 621-622, (1990)
Hamer et al, "Expression of the Chromosomal Mouse .beta.sup.maj -globin Gene Cloned in SV40", Nature, 281, 35-40 (Sep. 6, 1979)
Hamer et al., "SV40 Recombinants Carrying Rabbit -globin Gene Coding Sequences", Cell, 17: 725-735 (1979)
Hamer et al, "A Mouse Globin Gene Promoter is Functional in SV40", Cell, 21, 697-708 (Oct. 1980) Hammond et al., "Production, Utilization and Excretion of Erythropoietin: I. Chronic Anemias. Crisis III Erythropoietic Effects of Normal Plasma ", Ann. N.Y. Acad. Sci., 149, 516-527 (1968)
Hammond et al., "Paraneoplastic Erythrocytosis and Ectopic Erythropoietins", Ann. N. Y. Acad. Sci., 230: 219-27 (1974)
Hanahan et al., "Plasmid Screening at High Colony Density", Gene, 10, 63-67 (1980)
Hartman et al., "Human Influenza Virus Hemagglutinin is Expressed in Monkey Cells Using Simian Virus 40 Vectors", Proc. Natl. Acad. Sci. (USA), 79, 233-237 (1982)
Hauser et al., "Inducibility of Human .beta.-Interferon in Mouse L-celI Clones", Nature, 297, 650-654 (Jun. 24, 1982)
Haynes et al., "Constitutive, Long-term Production of Human Interferons by Hamster Cells Containing Multiple Copies of a Cloned Interferon Gene", Nucleic Acids Research, 11 (3), 587-607 (1983)
Haynes et al., "Production of a Glycosylated Human Protein by Recombinant DNA Technology", Proc. Takeda Sci. Found. Symp. Bioscl, 111-29 (1983)
Hellmann et al., "Familial Erythrocytosis with Over-production of Erythropoietin", Clin. Lab.
Haemat, 5, 335-342 (1983)
Hewick et al., "A Gas-Liquid Solid Phase Peptide and Protein Sequenator", J. Biol. Chem., 256, 7990-7997 (Aug. 1981)
Henry et al, "Clinical Use of Erythropoietin", Curr. Opin. Hematol, 2 (2): 118-124, (1995)
Higashi et al, "Structure and Expression of a Cloned cDNA for Mouse Interferon-.beta" J. Biol. Chem., 258 (15): 9522-9529 (1983)
Hokke et al, "Sialylated Carbohydrate Chains of Recombinant Human Glycoproteins Expressed in Chimose Hamster Ovary Cells Contain Traces of N-glycolyneuraminic Acid", FEBS Letters, 275, 9-14 (1990)
Horowitz et al., "Expression of Chimeric Genes in the Early Region of SV40", Mol. and Appl. Genet., 2: 147-159 (1983)
Howley et al., "Molecular Characterization of Papilloma Virus", Cold Spring Harbor Conf. Cell Proliferation, 7: 233-247 genomes (1980)
Hsiung et al., "Efficient Production of Hepatitis B Surface Antigen Using Bovine Papilloma Virus-metallothionein Vector", Mol. and Appl. Genet., 2: 497-506 (1987) Hu et al., "DNA Sequence Required for Initiation of Transcription in Vitro from the Major Late Promoter of Adenovirus 2", Proc. Nati Acad. Sci. (USA), 78: 820-824 (1981)
Huang et al., "Identification of Human Erythropoietin Receptor", Am. Soci. of Biological Chemists, Am. Assoc. of Immunologists, Fed. Pract. (USA) 43 (7) Abst. 2770, p. 1891 (1984)
Huang et al, "Characterization of Human Erythropoietin cDNA Clones," Am. Soc. Of Biological Chemists, Am. Assoc. of Immunologists, Fed. Pract. (USA), 43 (6) Abst. 1795, p. 1724
Imagawa et al., "Regulatory Elements of the Erythropoietin Gene", Blood, 77 (2) 278-285 (1991)
Imai et al., "Physicochemical and Biological Comparison of Recombinant Human Erythropoietin with Human Urinary Erythropoietin", J. Biochem, 107, 352-359 (1990)
Ismail et al., "An Opportunity to Intervene: Erythropoietin for the Treatment of Anaemia in Pre-Dialysis Patients, Nephrol Dial. Transplant., 13 (1): 14-17 (1998)
Itakura et al, "Synthesis and Use of Synthetic Oligonucleotides", Ann. Rev. Biochem., 53, 323-356 (1984)
Jacobs et al., "Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin", Nature, 313, 806-809 (Feb. 28, 1985) Jacobsen et al, "Relative Effectiveness of Phenylhydrazine Treatment and Hemophage in the Production of an Erythropoietic Factor ", Blood, 11: 937-945 (1956)
Jacobson et al., "Role of the Kidney in Erythropoiesis", Nature, 179: 633-634 (Mar 23, 1957)
Jaye et al, "Isolation of Human Anti-haemophilic Factor IX cDNA Clone Using a Unique 52-Base Synthetic Oligonucleotide Probé Deduced from the Amino Acid Sequence of Bovine Factor IX", Nucleic Acids Res. 11 (8), 2325-2335 (1983 )
Jelkman et al, "Extraction of Erythropoietin from Isolated Renal Glomeruli of Hypoxic Rats", Exp. Hematol., 11 (7), 581-588 (Aug. 1983)
Johnston et al, "Rapid Spontaneous Dihydrofolate Reductase Gene Amplification Shown by Fluorescence-activated Cell Sorting", Proc. Natl. Acad. Sci. (USA), 80: 3711-3715 (1983)
Kajimura et al, "Cloning the Heavy Chain of Human HLA-DR Antigen Using Synthetic Oligodeoxyribonucleotides as Hybridization Probes", DNA, 2 (3), 175-182 (1983)
Karin et al, "Expression and Regulation of a Human Metallothionein Gene Carried on an Autonomously Replicating Shuttle Vector", Proc. Natl. Acad. Sci. (USA), 80: 4040-4044 (1983)
Karn et al, "Novel Bacteriophage .lambda. Cloning Vector", P.N.A.S. (USA), 77, 5172-5176 (Sep. 1980) Katsuoka et al., "Erythropoietin Production in Human Renal Carcinoma Cells Passaged in Nude Mice and in Tissue Culture", Gann, 74, 534-541 (Aug. 1983)
Katz et al., "Studies on the Site of Production of Erythropoietin", Ann. N.Y. Acad. Sci., 149: 120-127 (1968)
Kaufman et al., "Amplified Dihydrofolate Reductase Genes in Instable Methotrexate-resistant Cells are Associated with Double Minute Chromosome", Proc. Natl. Acad. Sci. (USA), 76: 5669-5673 (1979)
Kaufman et al., "Construction of a Modular Dihydrofolate Reductase cDNA Gene: Analysis of Signals Utilized for Efficient Expression", Mol. Cell. Biol., 2: 1304-1319 (1982)
Kaufman et al, "Amplification and Expression of Sequences Cotransfected with a Modular Dihydrofolate Reductase Complementary DNA Gene", J. Mol. Biol, 159, 601-621 (1982)
Kaufman et al, "Expression and Amplification of DNA Introduced into Mammalian Cells", Gene Amplification, pp. 245-250, RT Schimke, Cold Spring Harbor, New York, New York (1982)
Kaufman et al., "Evolution of Chromosomal Regions Containing Transfected and Amplified Dihydrofolate Reductase Sequences", Mol. Cell. Biol., 3: 699-711 (1983)
Kaufman R et al, "Coamplification and Coexpression of Human Tissue-Type Plasminogen Activator and Murine Dihydrofolate Reductase Sequences in Chinese Hamster Ovary Cells", Mol. and Cell. Biol., 5 (7) 1750-9 (1985)
Kawai et al, "New Procedure for DNA Transfection with Polycation and Dimethyl Sulfoxide", Mol. Cell. Biol., 4 (6): 1172-1174 (1984)
Kennell, "Principles and Practices of Nucleic Acid Hybridization", Prog. Nucí. Acid Res. Mol. Biol., 11, 259-301 (1971)
Kieny et al., "Expression of Rabies Virus Glycoprotein from a Recombinant Vaccinia Virus", Nature, 312, 163-166 (1984)
Kingston et al., "Regulation of Transcription of the Adenovirus EII Promoter by Ela Gene Products: Absence of Sequence Specificity", Mol Cell. Biol., 4 (10): 1970-1977 (1984)
Koeller, "Clinical Guidelines for the Treatment of Cancer Related Anemia", Pharmacotherapy, 18 (1): 156-169 (1998)
Konrad, "Applications of Genetic Engineering to the Pharmaceutical Industry", Ann. N.Y. Acad. Sci., 413, 12-22 (1983)
Konwalinka et al, "A Miniaturized Agar Culture System for Cloning Human Erythropoietic Progenitor Cells", Exp. Hematol., 12, 75-79 (1984) Kornblihtt et al, "Isolation and Characterization of cDNA Clones for Human and Bovine Fibronectins", P.N.A.S. (USA), 80, 3218-3222 (June 1983)
Krane, "The Role of Erythropoietin in the Anemia of Chronic Renal Failure", Henry Ford Hosp. Med. J., 31 (3), 177-181 (1983)
Krantz, "Erythropoietin", Blood, 77 (3): 419-434
Krystal, "A Simple Microassay for Erythropoietin Based on .sup.3 H-Thymidine Incorporation into Spleen Cells from Phenylhydrazine Treated Mice", Exp. Hematol., 11 (7), 649-660 (Aug. 1983)
Krystal et al., "CM Affi-gel Blue Chromatography of Human Uriñe: A Simple One-step Procedure for Obtaining Erythropoietin Suitable for Vitro Erythropoietic Progenitor Assays", British J. Haematol., 58: 533-546 (1984)
Kuhn et al., "Gene Transfer, Expression, and Molecular Cloning of the Human Transferrin Receptor Gene", Cell, 37, 95-103 (1984)
Kurachi et al, "Isolation and Characterization of a Coding for Human Factor IX ', P.N.A.S. (USA), 79, 6461-6464 (Nov. 1982)
Kuratowska et al, "Studies on the Production of Erythropoietin by Isolated Perfiísed Organs':
Blood, 18: 527-534 (1961)
Kurtz, "A New Candidate for the Regulation of Erythropoiesis: Insulin-like Growth Factor I", FEBS Letters, 149 (1), 105-108 (Nov. 1982)
Kurtz, "Hormonal Inducibility of Rat 2u Globulin Genes in Transfected Mouse Cells", Nature, 291: 629-631 (1981)
Lafferty et al, "Ultrastructural, Immunocytochemical Localization of Presumptive Erythropoietin Binding Sites on Developing Erythrocytic Cells of Normal Human Bone Marrow", J. Hystochem. Cytochem., 29 (1): 49-56 (1981)
Lai et al., "Ovalbumin is Synthesized in Mouse Cells Transformed with the Natural Chicken Ovalbumin Gene", P.N.A.S. (USA), 77 (1), 244-248 (Jan. 1980)
Lai et al., "Structural Characterization of Human Erythropoietin", J. of Biol Chem., 261, 3116-3121 (Mar. 5, 1986)
Lai, "Technical Improvements in Protein Microsequencing", Analytica Chimica Acta, 163, 243-248 (1984)
Lange et al., "Application of Erythropoietin Antisera to Studies of Erythropoiesis", Ann. N.Y. Acad. Sci., 149: 281-291 (1968) Lange et al, "Antisera to Eiythropoietin: Partial Characterization of Two Different Antibodies", J. Lab. & Clin. Med., 73 (1): 78-90 (1969)
Lappin et al., "The Effect of Erythropoietin and Other Factors on DNA Synthesis by Mouse Spleen Cells", Exp. Hematol., 11 (7), 661-666 (Aug. 1983)
Lasky et al, "Production of an HSV Subunit Vaccine by Genetically Engineered Mammaliah Cell Lines", Modern Approaches to Vaccines, pp. 189-194, Chanock et al, Eds. Cold Spring Harbor Lab. (1984)
Lathe, "Synthetic Oligonucleotide Probes Deduced from Amino Acid Sequence Data", J. Mol. Biol., 183, 1-12 (1985)
Laub et al, "Expression of the Human Insulin Gene and cDNA in a Heterologous Mammalian System", J. Biol. Chem., 258 (10), 6043-6050 (May 25, 1983)
Laub et al, "Synthesis of Hepatitis B Surface Antigen in Mammalian Cells: Expression of the Entire Gene and the Coding Region", Viol, 48 (l): 271-280 (1983)
Lavi, "Carcinogen-mediated Amplification of Viral DNA Sequences in Simian Virus 40-Transformed Chimerus Hamster Embryo Cells", Proc. Natl. Acad. Sci. (USA), 78: 6144-6148 (1981) Law et al, "A Stable Bovine Papillomavirus Hybrid Plasmid that Expresses to Dominant Selective Trait", Mol. Cel. Biol., 3 (11): 2110-2115 (1983)
Lee et al., "Glucocorticoids Regulate Expression of Dihydrofolate Reductase cDNA in Mouse Mammary Tumor Chimeric Virus Plasmids", Nature, 294: 228-232 (1981)
Lee-Huang, "The Erythropoietin Gene", Oncogenes, Genes and Growth Factors, Chap. 7, pp. 199-222, Gordon Garaff, Ed., John Wiley & Sons, Boston, Massachusetts (1987)
Lee-Huang, "Cloning of Human Erythropoietin", Biophysical J., 45 (Part 2 of 2), ABT. M-PM-A12, p. 30th (1984)
Lee-Huang, "Monoclonal Antibodies to Human Erythropoietin", Abstract No. 1463, Fed. Proc., 41, 520 (1982)
Lee-Huang, "A New Preparative Method for Isolation of Human Erythropoietin with Hydrophobic Interaction Chromatography", Blood, 56 (4), 620-624 (Oct. 1980)
Lee-Huang, "Cloning and Expression of Human EPO cDNA in E. Coli", P.N.A.S. (US A), 81, 2708-2712 (May 1984)
Levine et al, "Perioperative Recombinant Human Erythropoietin", Surgery 106 (2): 432-438, (1989) Lewin, Genes, p. 307., John Wiley & Sons, Boston, Massachusetts (1983)
Lewis et al., "Selective Amplification of Polymofhic Dihydrofolate Reductase Gene Loci in Chinese Hamster Lung Cells", Proc. Natl. Acad. Sci. (USA), 79: 6961-6965 (1982)
Lewis et al, "Gene Amplification Accompanies Low Level Increases in the Activity of Dihydrofolate Reductase in Antifolate-resistant Chinese Hamster Lung Cells Containing Abnormally Banding Chromosomes", J. Cell. Biol, 94: 418-424 (1982)
Lin et al, "Cloning and Expression of the Human Erythropoietin Gene", Proc. Natl. Acad. Sci. (USA), 82, 7580-7584 (Nov. 1985)
Lin et al., "Monkey Erythropoietin Gene: Cloning, Expression and Comparison with the Human Erythropoietin Gene", Gene, 44, 201-209 (1986)
Lin et al., "Cloning of the Monkey EPO Gene", Abstract, J. Cell. Bioch., Suppl. 8B, p. 45 (Mar. 31-Apr. 24, 1984)
Lin et al, "Cloning and Expression of Monkey and Human Erythropoietin", Exp. Hematol. 12, 357 (1984)
Linman et al, "Studies on the Erythropoietic Effects of Hyperbaric Hyperoxia," Ann. N.Y. Acad. Sel, 149: 25-33 (1968) Lipschitz et al, "Effect of Age on Hematopoiesis in Man", Blood, 63 (3), 502-509 (Mar. 1983)
Liu Ch et al, "Direct Expression of Hepatitis B Surface Antigen in Monkey Cells from an SV40 Vector", DNA I: 213-221 (1982)
Lusky et al., "Inhibition of SV40 Replication in Simian Cells by Specific pBR DNA Sequences", Nature, 293: 79-81 (1981)
Maniatis et al, "The Isolation of Structural Genes from Libraries of Eucaryotic DNA", Cell, 15, 687-701 (Oct. 1978)
Maniatis et al, "Molecular Cloning, a Laboratory Manual", pp. 5, 197-199, 392-393, 479-487, 493-503 Cold Springs Harbor, N.Y. (1982)
Maxam et al, "Sequencing End Labeled DNA with Base-Specific Chemical Cleavages", Methods in Enzymol., 65, 499-560 (1980)
Macdougall et al., "Pharmacokinetics of Recombinant Human Erythropoietin in Patients on Continuous Ambulatory Peritoneal Dialysis", The Lancet, 425-427 (February 25,1989)
Macdougall et al, "Treating Renal Anaemia with Recombinant Huamn Erythropoietin: Practical Guidelines and a Clinic Algorithm", Br. Med. J., 300 (10): 655-659 (1990) Macdougall, "Meeting the Challenges of the New Millennium: Optimizing the Use of Recombinant Human Erythropoietin "Nephrol. Dial. Transplant., 13 (2): 23-27 (1998)
MacMillan et al., "Recombinant Human Erythropoietin in Children with Cancer", J. Pediatr. Hematol. Oncol., 20 (3): 187-189 (1998)
Maroteaux et al, "Sequences Involved in the Regulated Expression of the Human Interferon- 1 Gene in Recombinant SV40 DNA Vectors Replicating in Monkey Cells", The EMBO J. 1983, 2 (3): 325-332
McCormick et al, "Regulated Expression of Human Interferon Genes in Chinese Hamster Ovary Cells", DNA 2 (1): 86 Abst 86 (1983)
McCormick et al., "Inducible Expression of Amplified Human Beta Interferon Genes in CHO Cells", Mol. Cell. Biol., 4 (1): 166-172 (Jan. 1984)
McDonald et al., "Cloning, Sequence, and Evolutionary Analysis of the Mouse Erythropoietin Gene", Mol. Cell. Biol., 6 (3): 842-848
McGonigle et al, "Erythropoietin Deficiency and Inhibition of Erythropoiesis in Renal Insufficiency", Kidney Intl., 25 (2), 437-444 (1984)
Meier et al, "Alpha.sub.l -and Beta.sub.2 -Adrenergic Receptors Co-Expressed on Cloned MDCK Cells are Distinct Glycoproteins", Biochem. & Biophys. Res. Comm., 118 (1), 73-81 (1984)
Mellon et al., "Identification of DNA Sequences Required for Transcription of the Human .alpha.1-Globin Gene in a New SV40 Host- Vector System", Cell, 27, 279-288 (Dec. 1981)
Mellor et al., "Expression of Murine H-2K.sup.b Histocompatibility Antigen in Cells Transfected with Cloned H-2 Genes", Nature, 298: 529-534 (Aug. 1982)
Messing, "New M13 Vectors for Cloning", Methods in Enzymology, 101, 20-78 (1983)
"Methods in Yeast Genetics", P. 62, Cold Spring Harbor Lab., Cold Spring Harbor, New York (1983)
Miller et al, "Plasma Levéis of Immunoreactive Erythropoietin after Acute Blood Loss in Man", Brit. J. Haematol., 52, 545-549 (1982)
Mirand, "Extra-renal and Renal Control of Erythropoietin Production", Ann. N.Y. Acad. Sci., 149: 94-106 (1968)
Mirand et al., "Cupent Studies on the Role of Erythropoietin on Erythropoiesis", Ann. N.Y. Acad. Sci., 77: 677-702 (1959) Mishina et al., "Expression of Functional Acetylcholine Receptor from Cloned cDNA", Nature, 307: 604-608 (1984)
Mitrani-Rosenbaum et al, "Inducible Expression of the Human Interferon 1 Gene Linked to a Bovine Papilloma Virus DNA to Vector and Maintained Extrachromosomally in Mouse Cells", Mol. Cell. Biol., 3: 233-240 (1983)
M? Yake et al, "Purification of Human Erythropoietin", J. Biol. Chem., Vol. 252 (15), 5558-5564 (Aug. 1977)
Mladenovic et al, "Anemia of Chronic Kidney Failure (CRF) in the Sheep: Response to Erythropoietin (EP) In Vivo and In Vitro", Blood, 58 (5), Suppl. 1, 99a (1981)
Moia et al., "Improvement in the Haemostatic Defect of Uraemia after treatment with Recombinant Human Erythropoietin", The Lancet, 1227-1229 (November 28, 1987)
Moreau et al, "The SV40 72 Base Repair Repeat has a Striking Effect on Gene Expression both in SV40 and Other Chimeric Recombinants", Nucí. Acid Res., 9: 6047-6067 (1981)
Moriarty et al., "Expression of the Hepatitis B Virus Surface Antigen Gene in Cell Culture by Using a Simian Virus 40 Vector", P.N.A.S. (USA), 78 (4): 2606-10 (Apr. 1981)
Mujovic et al., "The Effect of Indomethacin on Erythropoietin Production in Dogs Following Renal Artery Constriction, The Possible Role of Prostaglandins in the Generation of Erythropoietin by the Kidney", J. Pharmacol. Exp. Ther., 191: 575-581 (1974)
Mulligan et al., "Factors Governing the Expression of a Bacterial Gene in Mammalian Cells," Mol. Cell. Biol., 1: 449-459 (1981)
Mulligan et al, "Synthesis of Rabbit -globin in Cultured Monkey Kidney Cells Following Infection with a SV40 -globin Recombinant Genome", Nature, 277: 108-114 (1979)
Mulligan et al, "Expression of a Bacterial Gene in Mammalian Cells", Science, 209: 1422-1427 (1980)
Mulligan et al, "Selection for Animal Cells that Express the Escherichia Coli Gene Coding for Xanthine-guanine Phosphoribosyltransferase", Proc. Natl. Acad. Sci. (USA), 78: 2072-2076 (1981)
Murphy et al, "The Role of Glycoprotein Hormones in the Regulation of Hematopoiesis" Acta. Haematologica Japónica, 46 (7), 1380-1396 (Dec. 1983)
Murray et al., "Construction and Use of a Dominant, Selectable Marker: a Harvey Sarcoma Virus-dihydrofolate Reductase Chimera", Mol. Cel. Biol., 3 (1): 32-43 (1983)
Myers et al., "Construction and Analysis of Simian Virus 40 Origins Defective in Tumor Antigen Binding and DNA Replication", P.N.A.S. (USA), 77, 6491-6495 (Nov. 1980)
Naets, "The Role of the Kidney in Erythropoiesis", J. Clin. Invest., 39: 102-110 (1960)
Nakao et al., "Erythropoiesis in Anephric or Kidney Transplanted Patients," Israel J. Med. Sci., 7: 986-989 (Jul.-Aug. 1971)
Nathan et al, "Erythropoietin and the Regulation of Erythropoiesis", N. England J. of Med., 308 (9), 520-522 (Mar. 3, 1983)
Naughton et al, "Evidence for an Erythropoietin-Stimulating Factor in Patients with Renal and Hepatic Disease", Acta. Haemat, 69, 171-179 (1983)
Naughton et al., "Evidence for a Hepatic-Renal Antagonism in the Production of Hepatic Erythropoietin," Ann. Clin. Lab. Sci., 13 (5), 432-438 (1983)
Nayak et al, "Characterization of Influenza Virus Glycoproteins Expressed from Cloned cDNAs in Prokaryotic and Eukaryotic Cells," Modern Approaches to Vaccines, pp. 165-172, Chanock et al., Eds., Cold Spring Harbor Lab. (1984)
Nielsen et al., "Erythropoietin b-D-galactosidase, The Generation, Purification and Use of Fusion Protein", J. Immunol. Meth., 111: 1-9 (1988) Nigg et al., "Immunofluorescent Localization of the Transforming Protein of Rous Sarcoma Virus with Antibodies against a Synthetic src Peptide", P.N.A.S. (USA), 79, 5322-5326 (Sep. 1982)
Nimtz et al., "Structures of Sialylated Oligosaccharides of Human Erythropoietin Expressed in Recombinant BHK-21 Cells", Eur. J. Biochem, 213, 39-56 (1993)
Nunberg et al., "Amplified Dihydrofolate Reductase Genes are Localized to a Homogeneously Staining Region of a Single Chromosome in a Methotrexate-resistant Chinese Hamster Ovary Cell Line", Proc. Natl. Acad. Sci. (USA), 75: 5553-5556 (1978)
O'Hare et al., "Transformation of Mouse Fibroblast to Methotrexate Resistance by a Recombinant Plasmid Expressing to Prokaryotic Dihydrofolate", Natl. Acad. Sci. (USA), 78: 1527-1531 (1981)
Ogle et al., "Production of Erythropoietin In Vitro: A Review", In Vitro, 14 (11), 945-949 (1978)
Okayama et al, "A cDNA Cloning Vector that Permits Expression of cDNA Inserts in Mammalian Cells", Mol. Cell. Biol., 3: 280-289 (1983)
Ohno et al., "Inducer-responsive Expression of the Cloned Human Interferon 1 Gene Introduced into Cultured Mouse Cells", Nucí. Acid Res., 10 (3): 967-977 (1982)
Osterborg, "Recombinant Human Erythropoetin (rHuEPO) Therapy in Patients with Cancer Related Anaemia: What Have We Learned ?," Med. Oncol., 15 (Suppl 1): 47-49 (1998) Pankratz et al, "A Simple 3 -Step Procedure for Purifying Baboon Urinary Erythropoietin to Apparent Homogeneity ", Exp. Hematol., 11, Supp. 14, Abst. 102 (1983)
Papayannopoulou et al, "On the In Vivo Action of Erythropoietin: A Quantitative Analysis", J. of Clin. Investigation, 51, 1179-1185 (1972)
Parekh et al., "N-Glycosylation and In Vitro Enzymatic Activity of Human Recombinant Tissue Plasminogen Activator Expressed in Chines Hamster Ovary Cells and a murine Cell Line", Biochemistry, 28, 7670-7679 (1989)
Parker et al, "Regulation of Simian Virus 40 Transcription: Sensitive Analysis of the RNA Species Present Early in Infections by Virus or Viral DNA", J. Virol., 31 (2): 360-369 (1979)
Pavlakis et al, "Regulation of a Metallothionein-growth Hormone Hybrid Gene in Bovine Papilloma Virus", Proc. Natl. Acad. Sci. (USA), 80: 397-401 (1983)
Pavlovic-Kentera et al., "Effects of Prostaglandin Synthetase Inhibitors, Salt Overload and Renomedullary Dissection on the Hypoxia Stimulated Erythropoietin Production in Rats", Exp. Hematol., 8 (Supp.8), 283-291 (1980)
Pennathur-Das et al, "Evidence for the Presence of CFU-E with Increased In Vitro Sensitivity to Erythropoietin in Sickle Cell Anemia", Blood, 63 (5), 1168-71 (May 1984) Perbal, "A Practical Guide to Molecular Cloning ", John Wiley & Sons, Boston, Massachusetts (1984)
Pitha et al., "Induction of Human .beta.-Interferon Synthesis with Poly (rl.cndot.rC) in Mouse Cells Transfected with Cloned cDNA Plasmids", P.N.A.S. (USA), 79, 4337-4341 (Jui, 1982)
Powell et al, "Human Erythropoietin Gene: High Level Expression in Stably Transfected Mammalian Cells and Chromosome Localization", Proc. Nati Acad. Sci. (USA), 83, 6465-6469 (Sep. 1986)
Quelle et al., "High-level Expression and Purification of a Recombinant Human Erythropoietin Producing a Baculovirus Vector", Blood, 74: 652-657 (1989)
Quelle et al., "Phosphorylatable and Epitope-Tagged Human Erythropoietins: Utility and Purification of Native Baculovirus-Derived Forms", Protein Expression and Purification 3, 461-469 (1992)
Radtke et al, "Serum Erythropoietin Concentration in Chronic Renal Failure: Relation to Degree of Anemia and Excretory Renal Function", Blood, 54 (4): 877-884 (1979)
Ramabhadran et al., "Synthesis and Glycosylation of the Common .alpha. Subunit of Human Glycoprotein Hormones in Mouse Cells", Proc. Nati Acad. Sci. (USA), 81, 6701-6705 (1984) Rambach et al., "Acid Hydrolysis of Erythropoietin", Proc. Soc. Exp. Biol., 99, 482-483 (1958)
Recny et al, "Structural Characterization on Natural Human Urinary and Recombinant DNA-derived Erythropoietin", Biol. Chem., 262 (35): 17156-17163 (1987)
Recormon® Products Monograph, Renal Anaemia, Boehringer Manheim GmbH
Reddy et al., "Nucleotide Sequence Analysis of the Proviral Genome of Avian Myelocytomatosis Virus (MC29)", Proc. Natl. Acad. Sci. (USA), 80: 2500-2504 (1983)
Reilly et al, "Use of Synthetic Oligonucleotides to Clone Genomic DNA: Isolation of a tRNA.sup.Phe Gene from Mouse", DNA 192 (1982)
Reissmann et al., "Erythropoietin Formation in Isolated Kidneys and Liver", Erithropoiesis, 71-77 (1962)
Rigby, "Expression of Cloned Genes in Eukaryotic Cells Using Vector Systems Derived from Viral Replicons", Genetic Engineering, R. Williamson, Ed., 3: 83-140, Academic Press, London, England (1982)
Rigby, "Review Article: Cloning Vectors Derived from Animal Viruses", J. Gen. Virol., 64: 255-266 (1983) Riggs et al., "Synthetic DNA and Medicine", Am. J. Hum. Genet., 31, 531-538 (1979)
Ringold et al, "Co-Expression and Amplification of Dihydrofolate Reductase cDNA and the Escherichia coli XGPRT Gene in Chinese Hamster Ovary Cells", J. Mol. & Appl., Genetics, 1 (3), 165-175 (1981)
Roh et al, "Plasma Disappearance of I.sup.125 labeled Human Uninary Erythropoietin in Rabbits", Fed. Proc., 29 (2), 782 Abst. 3030 (1970)
Rose et al, "Expression from Cloned cDNA of Cell-Surface Secreted Forms of the Glycoprotein of Vesicular Stomatitis Virus in Eucaryotic Cells", Cell, 30, 753-762 (1982)
Rosso et al., "Use of Erithropoietin in Oncology", TumoriJ, 83 (4 Suppl.2): 26-30, (1997)
Roth et al., "Influenza Virus Hemagglutinin Expression Is Polarized in Cells Infected with Recombinant SV40 Viruses Carrying Cloned Hemagglutinin DNA", Cell, 33, 435-443 (1983)
Rothmann et al., "Erythropoietin-Dependent Erythrocytosis Associated with Hepatic Angiosarcoma", J. Surg. Oncol., 20, 105-108 (1982)
Saito et al, "Translation of Human Erythropoietin-mRNAs", Exp. Hematol., 11 (14), 228 (1983)
Saito et al., "In Vitro Assay of Erythropoietin: Simple Determination in a Small Amount of Human Serum Samples", Jap. J. Med., 23 (1), 16-21 (Feb. 1984)
Sakata et al., "Plasma Erythropoietin Assay by a Fetal Mouse Liver Cell Culture Method with Special Reference to Effective Elimination of Erythroid Colony Inhibitor (s) in Plasma", Exp. Hematol., 15: 226-233 (1987)
Sambrook et al., "Expression of Proteins on the Cell Surface Using Mammalian Vectors", Experimental Manipulation of Gene Expression, p. 225-246, Academic Press, London, England (1983)
Sanders et al., "Amplification and Cloning of the Chinese Hamster Glutamine Synthetase Gene", The EMBO J., 3: 65-71 (1984)
Sanger et al., "DNA Sequencing with Chain-terminating Inhibitors", P.N.A.S. (USA), 74, 5463-5467 (Dec. 1977)
Sarver et al., "Bovine Papilloma Virus Deoxyribonucleic Acid: A Novel Eukaryotic Cloning Vector", Mol. Cell Biol., 1: 486-496 (1981)
Sarver et al, "Transformation and Replication in Mouse Cells of a Bovine Papillomavirus-pML2 Plasmid Vector that Can Be Rescued in Bacteria", Proc. Nati Acad. Sci. (USA), 79: 7147-7151 (1982) Sasaki, "Isolation of Erythropoietin by Monoclonal Antibody", Biomed. Biochim. Minutes., 42 (11/12), S202-206 (1983)
Sasaki et al., "Carbohydrate Structure of Erythropoietin Expressed in Chinese Hamster Ovary Cells by a Human Erythropoietin cDNA", J. Biol, Chem., 262 (25), 12059-12070 (Sep. 5, 1987)
Sasaki et al., "Site-specific Glycosilation of Human Recombinant Erythropoietin: Analysis of Glycopeptides of Peptides at Each Glycosilation Site by Fast Atom Bombardment Mass Spectrometry", Bioch., 27: 8618-8626 (1988)
Saveria Campo et al, "Transcriptional Control Signs in the Genome of Bovine Papillomavirus Type 1", Nature, 303: 77-80 (1983)
Scahill et al., "Expression and Characterization of the Product of a Human Immune Interferon cDNA Gene in Chinese Hamster Ovary Cells", Proc. Natl. Acad. Sci. (USA), 80, 4654-4658 (1983)
Schaffner W, "Direct Transfer of Cloned Genes from Bacteria to Mammalian Cells", Proc. Natl. Acad. Sel, 77: 2163-2167 (1980)
Schimke et al., "Chromosomal and Extrachromosomal Localization of Amplified Dihydrofolate Reductase Genes in Cultured Mammalian Cells", Cold Spring Harbor Symp. Quant. Biol., 45: 785-797 (1981) Schimke, "Gene Amplification in Cultured Animal Cells", Cell, 37: 705-713 (1984)
Seeburg et al., "Synthesis of Growth Hormone by Bacteria", Nature, 276, 795-798 (Dec. 1978)
Shahidi, "Androgens and Eiythropoiesis", N. England J. of Med., 289, 72-80 (June 12, 1973)
Sherwood et al, "Erythropoietin Titers in Sickle Cell Disease and Chronic Renal Failure", Blood, 58: 49a (1981)
Sherwood et al, "Extraction of Erythropoietin from Normal Kidneys", Endocrinology, 103 (3), 866-870 (1978)
Sherwood et al, "A Radioimmunoassay for Eiythropoietin", Blood, 54 (4), 885-893 (Oct. 1979)
Sherwood et al., "Erythropoietin Titers in Sickle Cell Disease and Chronic Renal Failure", Blood, 58 (1), Supp. 1, Abstract 105 (1981)
Shiramizu et al, "Human Renal Carcinoma Cells Secreting Erythropoietin In Vivo and In Vitro", Blood, 78 (10), Supp. 1 (Nov. 15, 1991)
Shoemaker et al., "Murine Erythropoietin Gene: Cloning, Expression, and Human Gene Homology", Mol. Cell. Biol., 6 (3): 849-858 Schumperli et al., "Efficient Expression of Escherichia Coli Galactokinase Gene in Mammalian Cells", Proc. Nati Acad. Sci. (USA), 79: 257-261 (1982)
Siddiqui, "NOTE: Expression of Hepatitis B Virus Surface Antigen Gene in Cultured Cells by Using Recombinant Plasmid Vectors", Mol. Cell. Biol., 3: 143-147 (1983)
Simonsen et al., "Isolation and Expression of an Altered Mouse Dihydrofolate Reductase cDNA", Proc. Natl. Acad. Sci. (USA), 50: 2495-2499 (1983)
Singer-Sam et al., "Isolation of a cDNA Clone for Human X-linked 3-phosphoglycerate Kinase by Use of a Mixture of Synthetic Oligodeoxyribonucleotides as a Detection Probe", P.N.A.S. (USA), 80, 802-806 (Feb. 1983)
Smith et al, "Construction and Characterization of an Infectious Vaccinia Virus Recombinant that Expresses the Influenza Hemagglutinin Gene and Induces Resistance to Influenza Virus Infection in Hamsters", Proc. Nati Acad. Sci. (USA), 80, 7155-7159 (1983)
Smith et al., "Production of Human Beta Interferon in Insect Cells Infected with a Baculovirus Expression Vector", Mol. Cell. Biol., 3 (12): 2156-2165 (1983)
Smith Dordal et al, "The Role of Carbohydrate in Erythropoietin Action", Endocrinology, 116 (6): 2293-2299 (1985) Sood et al, "Isolation and Partial Nucleotide Sequence of a cDNA Clone for Human Histocompatibility Antigen HLA-B by Use of an Oligodeoxynucleotide Primer ", Proc. Nati Acad. Sci. (USA), 78: 616-620 (1981)
Southern et al., "Transformation of Mammalian Cells to Antibiotic Resistance with a Bacterial Gene Under Control of the SV40 Early Region Promoter", J. Mol. Appl. Genet., 1 (4), 327-341 (1982)
Southern, "Detection of Specific Sequences Among DNA Fragments Separated by Gel Electrophoresis", J. Mol. Biol., 98, 503-517 (1975)
Spellman et al., "Carbohydrate Structure of Recombinant Soluble Human CD4 Expressed in Chinese Hamster Ovary Cell", Biochemistry, 30 (9), 2395-2406 (1991)
Spellman et al., "Carbohydrate Structure of Human Tissue Plasminogen Activator Expressed in Chinese Hamster Ovaiy Cells", J. of Biol. Chem., 264 (24), 14100-14111 (Aug. 26, 1989)
Spivak, "Erythropoietin: A Brief Review", Nephron, 52: 289-294 (1989)
Spivak et al, "The In Vivo Metabolism of Recombinant Human Erythropoietin in the Rat", Blood, 73 (1): 90-99 (1989)
Stark et al, "Gene Amplification", Ann. Rev. Biochem., 53: 447-91 (1984) Steinberg et al, "Erythropoietin Kinetics in Rats: Generation and Clearance", Blood, 67 (3): 646-649 (1986)
Stenlund et al, "Secretion of Hepatitis B Virus Surface Antigen from Mouse Cells Using an Extra-chromosomal Eucaryotic Vector", The EMBO J., 1983, 2 (5): 669-673
Stephenson et al., "Quantitative Assay Method for Erythropoietin In Vitro", Endocrinology, 88: 1519-1520 (1971)
Storring et al., "The International Standard for Recombinant DNA Derived Erythropoietin: Collaborative Study of Four Recombinant DNA Derived Erythropoietins and Two Highly Purified Human Urinary Erythropoietins", J. of Endo., 134, 459-84 (1992)
Stratowa et al, "Recombinant Retroviral DNA Yielding High Expression of Hepatitis B Surface Antigen", The EMBO J., 1 (12): 1573-1578 (1982)
Subramani et al, "Expression of the Mouse Dihydrofolate Reductase Complementary Deoxyribonucleic Acid in Simian Virus SV 40 Vectors", Mol Cell. Biol., 1: 854-864 (1981)
Sue et al., "Site-specific Antibodies to Human Erythropoietin Directed to the NH.sub.2 -tepninal Region", Proc. Nat. Acad. Sci. (USA), 80, 3651-3655 (1983)
Suggs et al, "Use of Synthetic Oligodeoxyribonucleotide for the Isolation of Specific Cloned DNA Sequences," Developmental Biology Using Purified Genes, 683-693, D. Brown, Ed. (1981)
Suggs et al., "Use of Synthetic Oligonucleotides as Hybridization Probes: Isolation of Cloned cDNA Sequences for Human B.sub.2 -microglobulin", P.N.A.S. (USA), 78, 6613-6617 (1981)
Sveda et al, "Functional Expression in Primate Cells of Cloned DNA Coding for the Hemagglutinin Surface Glycoprotein of Influenza Virus", Pros. Natl. Acad. Sci. (USA), 78 (10): 5488-5492 (Sep. 1981)
Sytowski et al., "The Biochemistry of Erythropoietin: An Approach to its Mode of Action", Exp. Hematol., 8 (Supp.8), 52-63 (1980)
Sytowski et al, "A Novel Radioimmunoassay for Human Erythropoietin Using a Synthetic NH.sub.2 -Terminal Polypeptide and Anti-Peptide Antibodies", J. Immunol. Methods, 69, 181-186 (1984)
Szostak et al., "Hybridization with Synthetic Oligonucleotides", Meth. in Enzymol, 68, 419-428 (1979)
Takeuchi et al., "Relation between Sugar Chain Structure and Biological Activity of Recombinant Human Erythropoietin Produced in Chinese Hamster Ovary Cells", Proc. Natl. Acad. Sci. (USA), 86, 7819-7822 (Oct. 1989) Takeuchi, "Comparative Study of the Asparagine-linked Sugar Chains of Human Erythropoietin Purified from Uriñe and the Culture Medium of Recombinant Chinese Hamster Ovary Cells", J. Biol. Chem., 263 (8), 3657-3663 (Mar. 15, 1988)
Tambourin et al, "Production of Erythropoietin-like Activity by a Murine Erythroleukemia Cell Line", P.N.AS. (USA), 80, 6269-6273 (1983)
Taub et al., "An Improved Method for Preparing Large Arrays of Bacterial Colonies Containing Plasmids for Hybridization: In Situ Purification and Stable Binding of DNA on Paper Filters", Chemical Abstracts, 97 (23), 164, Abstract No. 194002y (Dec 12, 1982)
Taub et al, "An Improved Method for Preparing Large Arrays of Bacterial Colonies Containing Plasmids for Hybridization: In Situ Purification and Stable Binding of DNA on Paper Filters", Anal. Biochem., 126, 222-230 (1982)
Testa et al, "Role of Purified Erythropoietin in the Amplification of the Erythroid Compartment", Exp. Hematol., 8 (Supp.8), 144-152 (1980)
Tong et al., "The Formation of Erythrocyte Membrane Proteins during Erythropoietin-induced Differentiation", J. Biol. Chem., 256 (24), 12666-12672 (Dec. 25, 1981)
Toóle et al, "Molecular Cloning of a cDNA Encoding Human Antihaemophilic Factor", Nature, 312, 342-347 (Nov. 8, 1984) Tsuda et al, "Comparative Structural Study of N-Linked Oligosaccharides of Urinary and Recombinant Erythropoietins", Biochemistry, 27 (15), 5646-5654 (1988)
Tsuda et al, "The Role of Carbohydrate in Recombinant Human Erythropoietin", Eur. J. Biochem., 188: 405-411 (1990)
Thummel et al., "Construction of Adenovirus Expression Vectors by Site-directed In Vivo Recombination", J. Mol. Appl. Genet., 1: 435-446 (1982)
Thummel et al, "Translational Control of SV40 T Antigen Expressed from the Adenovirus Late Promoter", Cell, 33: 455-464 (1983)
Thurmon et al, "Hemoglobin Switching in Nonanemic Sheep, III, Evidence for Presumptive Identity between the A C Factor and Erythropoietin", Blood, 36 (5): 598-606 (1970)
Udupa et al, "Erythropoiesis in the Aged Mouse", Lab. Clin. Med., 103 (4), 574-580; 581-588 (1984)
Umemura et al., "The Mechanism of Expansion of Late Erythroid Progenitors During Erythroid Regeneration: Target Cells and Effects of Erythropoietin and Interleukin-3", Blood, 73 (7) 1993-1998 (1989)
Urlaub et al., "Isolation of Chinese Hamster Cell Mutants Deficient in Dihydrofolate Reductase Activity", Proc. Nat. Acad. Sci. (USA), vol. 77 (7), 4216-4220 (Jui 1980)
Van Stone et al, "Effect of Erythropoietin on Anemia of Peritoneally Dialyzed Anephric Rats," Kidney Intl., 15, 370-375 (1979)
Vedovato et al., "Erythropoietin Levéis in Heterozygous Beta-Thalassemia", Acta. Haematol., 71, 211-213 (1984)
Viera et al., "The pUC Plasmids, an M13mp7-derived System for Insertion Mutagenesis and Sequencing with Synthetic Universal Primers," Gene, 19, 259-268 (1982)
Wahl et al, "Effect of Chromosomal Position on Amplification of Transfected Genes in Animal Cells", Nature, 307: 516-520 (1984)
Wasley et al, "The Importance of N-and O-Linked Oligosaccharides for the Biosynthesis and In Vitro and In Vivo Biologic Activities of Erythropoietin", Blood, 77 (12): 2624-2632 (1991)
Walker et al, Techniques in Molecular Biology, p. 280, Macmillan Pub. Co., New York, New York (1983)
Wallace et al., "The Use of Synthetic Oligonucleotides as Hybridization Probes, II, Hybridization of Oligonucleotides of Mixed Sequence to Rabbit. Beta. -globin DNA", Nuc. Acids Res., 9 (4), 879-894 (1981) Wang et al., '? Nhanced Production of Hepatitis B Surface Antigen in NTH 3T3 Fibroblast by Using Extrachromosomally Replicating Bovine Papillomavirus Vector ", Mol. Cell. Biol., 3 : 1032-1039 (1983)
Wang et al., "Some Chemical Properties of Human Erythropoietin", Endocrinology, 116 (6), 2286-2292 (1985)
Wang et al., "Renal and Extrarenal Erythropoietin Production in Male and Female Rats of Various Ages", J. Lab. Clin. Med., 79 (2), 181-186 (Feb. 1972)
Watson et al., "Structure Determination of the Intact Major Sialylated Oligosaccharide Chains of Recombinant Human Erythropoietin Expressed in Chinese Hamster Ovary Cells", Glycobiology, 4 (2) 227-237 (1994)
Weiland et al, "In Vivo Activity of Asialo-Erythropoietin in Combination with Asia-Glycoproteins", Blut, 44 (3), 173-175 (1982)
Weiss et al, "Characterization of a Monoclonal Antibody to Human Erythropoietin", P.N.A.S. (USA), 79, 5465-5469 (1982)
Weiss et al., "Studies of the Pathogenesis of Anemia of Inflammation: Mechanism of Impaired Erythropoiesis", Am. J. Vet. Res., 44 (10), 1832-1835 (Oct. 1983) Weissman et al., "Structure and Expression of Human JJFN-. Alpha. Genes", Phil Trans. R. Soc. Lond., B299, 7-28 (1982)
White et al, "Studies on Erythropoietin", Recent Progr. Hormone Res., 16: 219-262 (1960)
Wickens et al., "Expression of a Chicken Chromosomal Ovalbumin Gene Injected into Frog Oocyte Nucleus", Nature, 285: 628-634 (Jun 26, 1980)
Wide et al, "Molecular Charge Heterogeneity of Human Serum Erythropoietin", British J. Haemat, 76, 121-127 (1990)
Wigler et al., "Transformation of Mammalian Cells with Genes from Procaryotes and Eucaryotes", Cell, 16: 777-785 (1979)
Wigler et al, "Biochemical Transfer of Single-copy Eucaryotic Genes Using Total Cellular DNA as Donor", Cell, 14: 725-731 (1978)
Wigler et al., "Transfer of Purified Herpes Virus Thymidine Kinase Gene to Cultured Mouse Cells", Cell, 11: 223-232 (1977)
Wigler et al, "Transformation of Mammalian Cells with an Amplifiable Dominant-Acting Gene", Proc. Natl. Acad. Sci. (USA), 77: 3567-3570 (1980) 8
Wiktor et al., "Protection from Rabies by a Vaccinia Recombinant Virus Containing the Rabies Virus Glycoprotein Gene", Proc. Natl. Acad. Sci. (USA), 81, 7194-7198 (1984)
Winnearls, "Recombinant Human Erythropoietin: 10 Years of Clinical Experience", Nephrol. Dial. Transplant., 13 (2): 3-8 (1998)
Wojchowski et al, "Active Human Erythropoietin Expressed in Insect Cells Using a Baculovirus Vector: A Role for N-linked Oligosaccharide", Bioch. Bioph. Acta, 910: 224-232 (1987)
Wojchowski et al, "Site-specific Antibodies to Human Erythropoietin: Immunoaffinity Purification of Urinary and Recombinant Hormone", Bioch. Bioph. Acta., 913: 10-178 (1987)
Woo, "A Sensitive and Rapid Method for Recombinant Phage Screening", Methods in Enzymology, 68, 389-395 (1979)
Wood et al., "Expression of Active Human Factor VIII from Recombinant DNA Clones", Nature, 312, 330-336 (Nov. 22, 1984)
Wright et al, "Regulated Expression of the Human-globin Gene Family in Murine Erythroleukaemia Cells", Nature, 305: 333-336 (1983)
Yajima et al., "Comparative Studies in Induction of Micronuclei by Three Genetically Recombinant and Urinary Human Erythropoietins", Mutagenesis, 8 (3): 237-241, (1993) Yanagawa et al, "Hybridomas for Production of Monoclonal to Human Erythropoetin" , Blood, 64 (2), 357-364 (Aug. 1984)
Yanagawa et al., "Isolation of Human Erythropoietin with Monoclonal Antibodies", J. Biol. Chem., 259 (5), 2707-2710 (Mar. 10, 1984).
Yanagi et al, "Recombinant Human Erythropoietin Produced by Namalwa Cells", DNA 8 (6), 419-427 (1989)
Yuen et al, "The Spectrum of N-linked Oligosaccharide Structures Detected by Enzymic Microsequencing on a Recombinant Soluble CD4 Glycoprotein from Chinese Hamster Ovary Cells", Eur. J. Biochem., 192, 523-528 (1990)
Zain et al, "Nucleotide Sequence Analysis of the Leader Segments in a Cloned Copy of Adenovirus 2 Fiber mRNA", Cell, 16: 851-861 (1979)
Zieg et al, "Properties of Single-step Mutants of Syrian Cell Lines Resistant to N- (Phosphonacetyl) -L-Aspartate Hamster," Mol. Cell. Biol., 3 (11): 2089-2098 (1983)
Zinn et al., "Regulated Expression of an Extrachromosomal Human .beta.-interferon Gene in Mouse Cells", P.N.AS. (USA), 79, 4897-4901 (Aug. 1982)
Claims (16)
- Claims
- Having described and exemplified the nature and main object of the present invention, as well as the manner in which it can be carried out, it is claimed to claim as property and exclusive rights: 1. A procedure for the purification of erythropoietin. recombinant human from cell culture supernatants characterized by including the following steps: a) differential precipitation; b) hydrophobic interaction chromatography; c) concentration and diafiltration; d) anion exchange chromatography; e) cation exchange chromatography; f) concentration and diafiltration; g) gel permeation chromatography. 2. A method, as characterized in claim 1, wherein steps a) through g) are performed in the following sequence: a), b), c), d), e), f) and g).
- 3. A method, as characterized in claim 1, wherein steps a) through g) are performed in the following sequence: a), c), d), e), b), f) and g).
- 4. A process, as characterized in claim 1, wherein step a) comprises adding ammonium sulfate to the culture supernatant, followed by centrifugation.
- 5. A method, as characterized in claim 1, wherein step b) comprises using a hydrophobic interaction matrix.
- 6. A process, as characterized in claim 5, wherein the hydrophobic interaction matrix used is Phenyl Sepharose 6 Fast Flow.
- 7. A method, as characterized in claim 1, wherein step d) comprises using an anion exchange matrix.
- 8. A process, as characterized in claim 7, wherein the anion exchange matrix used is Q-Sepharose Fast Flow.
- 9. A method, as characterized in claim 1, wherein step e) comprises using a cation exchange matrix.
- 10. A process, as characterized in claim 9, wherein the cation exchange matrix used is SP-Sepharose Fast Flow.
- 11. A method, as characterized in claim 1, wherein step g) comprises using a molecular exclusion matrix.
- 12. A process, as characterized in claim 11, wherein the molecular exclusion matrix used is Sephacryl S-200 HP.
- 13. An erythropoietin, substantially pure, obtained according to the method characterized in claim 1.
- 14. An erythropoietin, as characterized in claim 13, wherein said substance has a purity greater than 99% as determined by a gel electrophoresis analysis of polyacrylamide (SDS-PAGE) and reversible phase high-pressure liquid chromatography and molecular exclusion chromatography.
- 15. An erythropoietin, as characterized in claim 13, wherein said substance is composed of a series of isoforms of isoelectric point comprised between 3.0 and 4.5.
- 16. An erythropoietin, as characterized in claim 13, wherein said substance shows total homology to the natural human erythropoietin having the following amino acid sequence SEQ ID NO: 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ARP98-01-05610 | 1998-11-06 | ||
ARP99-01-00680 | 1999-02-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA99010045A true MXPA99010045A (en) | 2000-12-06 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2159814C2 (en) | Erythropoietin analogue | |
AU697453B2 (en) | Erythropoietin analog compositions and methods | |
US4703008A (en) | DNA sequences encoding erythropoietin | |
EP0148605B1 (en) | Production of erythropoietin | |
US5621080A (en) | Production of erythropoietin | |
AU2002300734B2 (en) | Fusion protein having enhanced in vivo erythropoietin activity | |
CZ291515B6 (en) | Isolated biologically active erythropoietin isoform, process of its preparation and pharmaceutical composition based thereon | |
JPH0655144B2 (en) | DNA sequence encoding erythropoietin, recombinant DNA vector and transformant | |
KR20020046150A (en) | Fusion protein having the enhanced in vivo activity of erythropoietin | |
JP4345077B2 (en) | Recombinant human erythropoietin with an advantageous glycosylation profile | |
MXPA99010045A (en) | Procedure for the purification of recombinant human erythropoyetine from recombinant cell culture supplementers and human erythropoyetin obtained with such procedime | |
MXPA99010043A (en) | Procedure of massive mammal cell culture for the obtaining of humanarecombinant erythropoyetine and recombinant human erythropoyetine obtained with such procedimie | |
MXPA99010042A (en) | Recombinant human erythropoyetine productive cellular line and the recombinant human erythropoyetine produced by this cell | |
Goldwasser et al. | Erythropoietin: the primary regulator of red cell formation | |
JPH0144317B2 (en) | ||
BG60508B2 (en) | Dna sequences encoding erythropoietin |